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As the third most commonly diagnosed malignancy and second leading cause of 
cancer-related death, colorectal cancer remains a major global healthcare concern.  
Despite numerous studies to elucidate the mutations involved in tumorigenesis and assist 
with the prognostic stratification of patients, individual outcomes and therapeutic 
responses remain unpredictable.  In this study, we performed a retrospective analysis of 
the clinical and pathological features of colorectal cancers diagnosed in the Upper 
Peninsula of Michigan.  We then characterized the frequency and diversity of six 
molecular markers (MMR, BRAF, NRAS, KRAS, PIK3CA, PD-L1) in matched samples 
belonging to 120 patients in our cohort and correlated the findings with cancer registry 
data. 
PCR-based assays were performed to identify point mutations in the RAS, RAF 
and PIK3CA pathways using zinc formalin-fixed, paraffin-embedded blocks belonging to 
the patients in our cohort. Additionally, immunohistochemical stains were prepared to 
assess DNA mismatch repair protein expression and PD-L1 status in the tumor cells.  
Individual mutations were correlated with the clinical -pathological features of CRC in 
patients.  We noted a higher frequency of primary tumors arising in the proximal colon, 
as well as a potential prognostic value in KRAS and PIK3CA mutation testing.  We 
believe this is the first population-based study to characterize and correlate mutations 
with clinicopathological variables in colorectal cancer patients from the Upper Peninsula 
of Michigan.  The findings presented here provide additional insight regarding the tumor 
xii 
microenvironment at various stages of disease and may lead to more effective patient 
management strategies as well as the development of new companion diagnostics.  
1 
1 Introduction and Literature Review 
Although colorectal cancer (CRC) continues to be extensively studied, it remains 
the third most commonly diagnosed malignancy and second leading cause of cancer-
related death in the world 1,2 .  In 2019, CRC is projected to account for 8.3% of all new 
cancer diagnoses and approximately 150,000 new diagnoses this year 2.  The estimated 
five- year relative survival rate for CRC patients is approximately 64%, however, overall 
survival rates vary significantly depending on a number of factors, including the 
histological stage and grade of the tumor at the time of diagnosis, the comorbidities of the 
patient and the chemosensitiviy of the tumor cells 2, 3. 
1.1 Genes and Molecular Pathways Involved in Tumorigenesis 
The genes and signaling pathways involved in CRC tumorigenesis have been well 
documented and include WNT/APC/ β-Catenin, MAPK, PI3K/AKT/ mTOR, TGFβ, and 
TP53 4,5,6.  These pathways are responsible for regulating normal cell growth, cellular 
differentiation, proliferation and survival within the colonic crypts.  Additionally, each 
pathway confers biological properties that maintain the composition of the extracellular 
matrix.  The WNT pathway produces proteins that maintain homeostasis of the stem cell 
niche within the intestinal epithelium and regulate angiogenesis as well as the remodeling 
of existing vasculature6,7, 8.  The MAPK signaling cascade regulates cell migration and 
apoptosis9.  The PI3K/ AKT pathway controls cytoskeletal rearrangement, protein 
translation and cell survival10.   
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Phenotypically, there are three molecular pathways involved in colorectal carcinogenesis, 
including the chromosomal instability pathway (CIN), the CpG Island methylator 
phenotype (CIMP), and the microsatellite instability pathway (MSI).  These pathways 
have unique characteristics but all result from the accumulation of genetic and epigenetic 
changes that facilitate the malignant transformation of the colonic epithelium.  
Additionally, the development of neoplastic precursor lesions, such as adenomas or 
serrated polyps, proceed the formation of malignant lesions11,12,13,14. 
The CIN pathway is associated with approximately 70% of sporadic CRCs and is 
characterized by large structural chromosomal changes that may include gains, losses, 
insertions or deletions and result in aneusomy8,13.  In CRC, truncating mutations in the 
Adenomatous Polyposis Coli (APC) tumor suppressor gene result in the activation of the 
Wnt pathway which initiates tumorigenesis. Dysregulation of Wnt pathway results in 
chromosomal instability and the acquisition of KRAS mutations as carcinogenesis 
progresses8,14,15.   
The microsatellite instability pathway results from defects in the DNA mismatch 
repair (MMR) system and is associated with approximately 15% of sporadic CRC8,15.  
DNA mismatch repair proteins are normally expressed by proliferating cells and correct 
base substitution mismatches and abnormal insertion-deletion loops arising in repetitive 
DNA sequences known as microsatellites16.  Hypermethylation of mismatch repair 
(MMR) genes results in a loss of function of the MMR machinery and accelerate the 
accumulation of mutations, especially within repetitive, microsatellite regions8,15.   
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Consequently, nucleotide expansions occurring in the exons of genes result in frameshift 
mutations and mutations in tumor-related genes14.  
Microsatellite instability may also be inherited as a germline mutation via Lynch 
Syndrome.  Individuals with Lynch syndrome inherit a mutant MMR gene and 
consequently have somatic cells that contain one normal and one non-functioning MMR 
gene.  During tumorigenesis, the normal gene MMR gene may become mutated or 
epigenetically silenced, resulting in the loss of function of the MMR machinery and 
acquisition of microsatellite instability in the malignant cells8,14,15.  
The CpG Island Methylator Phenotype (CIMP) pathway is characterized by 
global hypermethylation of CpG island promoters that result in the epigenetic silencing of 
MMR proteins and tumor suppressor genes8,14,15,17.   CIMP is believed to be an 
underlying factor in MSI, since the latter is often associated with promoter methylation of 
the MLH1 MMR gene18.   CIMP tumors tend to be hypermutated, with many 
demonstrating concomitant BRAF mutations8,15,18. 
1.2 Heterogeneity of Colorectal Cancer 
A plethora of research has been performed to elucidate the heterogeneity of CRC, 
a hallmark feature of this malignancy.   CRC tumors are comprised of a highly diverse 
populations of cells, including malignant differentiated colonic cells, colon cancer stem 
cells, fibroblasts, immune cells and endothelial cells, each interacting with its neighbors 
through cell signaling proteins and growth factors in the microenvironment19.   Mutations 
are believed to be sequentially acquired as a result of genomic instability and contribute 
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to the overall genetic diversity of the tumor20, 21.  The protective tumor microenvironment 
facilitates tumor development and progression by supporting angiogenesis, epithelial-to-
mesenchyme transition and adaptive immunity22,23.  
1.3 The Role of Programmed Cell Death Ligand (PD-L1) in 
Colorectal Cancer 
 Programmed cell death ligand 1 (PD-L1) is a transmembrane protein that 
modulates the immune system by binding to receptors on T-cell lymphocytes and 
antigen- presenting cells, thereby inhibiting immune responses24, 25, 32, 33.  PD-L1 may 
also be located on the surface of malignant cells and tumor-infiltrating immune cells 
(TIC) within the tumor microenvironment5.  Increased PD-L1 expression on tumor cells 
may contribute to T-cell “exhaustion” and suppression of the immune system within the 
tumor.   Increased expression of PD-1 is associated with a poor prognosis in many 
malignancies, including melanoma, esophageal, gastric, hepatocellular and urothelial 
carcinomas, and is believed to be associated with tumor invasion in CRC, although this 
has not been fully elucidated24, 25, 32, 33.   
IN CRC, PD-L1 expression has not been shown to occur in a higher frequency in 
either gender26.   Increased PD-L1 expression and BRAF mutations with microsatellite 
instability have been associated with a poor prognosis.  PD-L1 expression analyses might 
be useful in identifying patients who’d benefit from PD-L1 immunotherapies27.   
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1.4 Microsatellite Instability Status 
The mechanisms associated with DNA damage have been well-documented in the 
literature and may occur spontaneously during replication processes or from exposure to 
various environmental factors including chemicals, radiation, radon and UV light.   DNA 
repair mechanisms maintain the integrity of DNA and mitigate nucleotide errors through 
a variety of processes, including mismatch repair (MMR), base excision repair (BER), 
and nucleotide excision repair(NER)16.    
In humans, there are four clinically important DNA mismatch repair proteins 
(MMR), including MLH1, MSH2, MSH6, and PMS2.  In normal repair processes, the 
MMR proteins form heterodimers (MLH1/PMS2, and MSH2/MSH6, respectively) and 
excise single nucleotide mismatches and insertion / deletion loops from the DNA 
strand16,28.  Epigenetic changes to the MMR genes, such as hypermethylation of the 
promoter on the MLH1 gene, result in the loss of expression and consequent dysfunction 
of the DNA MMR proteins14,15,28.    Deficiencies or dysfunction of the  MMR proteins 
correlate with microsatellite instability in the tumor 34, 35, 36, 37.   
Short segments of repeating nucleotides or microsatellites are located throughout 
the genome.  These repeats are prone to nucleotide mismatch errors arising from 
polymerase slippage during the replication process29.  The MMR pathway plays a key 
role in recognizing and excising errors, as described above.  If the MMR proteins are 
deficient or not functioning properly, alterations occurring during the replication process 
are not corrected, and result in the accumulation of mutations14,15,28.   
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Microsatellite instability (MSI) or MMR dysfunction is noted in approximately 
15% of CRC tumors, with MLH1 being the most frequently deficient MMR protein23.   
MSI has both prognostic and therapeutic implications.  Primary tumors that have 
deficient MMR proteins tend to respond to fluoropyrimidine therapy (5-flurouracil) and 
consequently, confer improved outcomes23,30.   Patient’s whose tumors are MSI may also 
benefit from immunotherapy27.   
1.5 Mutations in the MAPK Pathway and CRC 
The relationship between mutations in the MAPK pathway and the development 
and progression of cancer have been well documented, with the RAS and RAF oncogenes 
being the most frequently encountered somatic mutations resulting in cancer15.  RAS and 
RAF gain-of-function mutations bypass prerequisite EGFR signaling and independently 
activate the MAPK pathway31.  RAS and RAF mutations rarely occur concomitantly, 
suggesting that these tumorigenic pathways differ and offer no selective advantage for 
tumors to harbor both5.  
1.6 KRAS 
The KRAS oncogene is responsible for activating the MAPK and 
PIK/AKT/mTOR signaling pathways by transmitting signals received from receptor 
tyrosine kinase (RTK) to BRAF and PIK3CA, respectively9, 32, 23.  Point mutations in the 
KRAS gene activate signaling pathways, independent of growth factor / RTK binding.  
The KRAS gene is one of the most frequently mutated genes associated with cancer and 
has been reported in numerous malignancies, including colon cancer, 
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cholangiocarcinoma, pancreatic and lung cancer 33, 34.   The diversity and frequency of 
KRAS mutations is a hallmark feature of CRC, with approximately 40% of CRC tumors 
harboring at least one KRAS mutation9,34,35.  Anatomically, KRAS mutations are 
distributed throughout the colon, with females more likely to have a KRAS mutation in 
transverse and descending colon compared to males35.  In CRC, KRAS mutation analysis 
is currently conducted to predict the efficacy of anti-EGFR therapy, however, research is 
revealing that it may have a prognostic value as well34,36, 37.  KRAS mutations primarily 
cluster around mutational hotspots in codons 12 and 139,32,35.    KRAS mutation G12V 
has been associated with more advanced malignancies and confers a poorer prognosis 
compared to other KRAS mutations9,38, 34.  Similarly, in recurrent and metastatic 
colorectal cancer (mCRC), KRAS G13D is associated with poor patient outcomes32.  
KRAS mutations may also be found in codons 61 and 146, with the later noted almost 
exclusively in CRC34.  The significance of mutations in codons 61 and 146 has not been 
fully elucidated, as the recommendation to include these mutations as part of extended 
mutation analyses in the clinical laboratory was recently made9,32, 39.    
1.7 NRAS 
Approximately 2-4% of CRC have NRAS mutations5,9.  NRAS mutations cluster 
within codons 12, 13 and 61 and may represent a distinct subtype of CRC, because they 
demonstrate different clinicopathological characteristics vs those associated with other 
RAS-family genes32.  Clinically, NRAS mutations arise in mucinous adenocarcinomas in 
the distal colon and are demographically associated with older patients.  NRAS are often 
associated with localized disease and confer a better prognosis compared to KRAS40.   
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1.8 BRAF 
BRAF mutations are associated with a variety of malignancies, including 
melanoma, papillary thyroid carcinoma, colorectal carcinoma, ovarian and lung 
cancers41.  They are identified in 10-15% of CRC tumors and are typically mutually 
exclusive of KRAS mutations9,30,32.  The most common BRAF mutation, (V600E), is 
associated with colon cancer arising in the proximal colon.  Phenotypically, BRAF 
V600E is frequently identified in older, female patients with poorly-differentiated 
mucinous adenocarcinomas that demonstrate MSI 9,30,32,42,43.   Patients with BRAF 
mutations typically have a poorer overall survival when compared to patients whose 
malignancies demonstrate wild-type BRAF20, 23.   Consequently, BRAF mutation analysis 
is useful for the prognostic stratification of patients with colorectal cancer and also serves 
as a biomarker to assist oncologists with predicting patient response to anti-EGFR 
therapies44.    
1.9 PIK3CA 
The PIK3CA gene is responsible for activating the PIK/AKT/mTOR pathway10,45.   
Amino acid substitutions in the p110α protein have been associated with a variety of 
cancers, including glioblastoma, gastric, head and neck, endometrial, breast, ovary, lung 
and colorectal cancers45, 46, 47.  Point mutations in the PIK3CA gene are present in 
approximatley 10-20% of CRCs and are most frequently clustered in exons 9 and 2035,47.   
PIK3CA mutations are typically identified in poorly differentiated adenocarcinomas and 
concurrent metastatic liver samples42  Additionally, PIK3CA mutations present 
concomitantly with KRAS mutations and have been associated with chemoresistance42,48. 
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Patients with PIK3CA / KRAS co-mutations reportedly have poor outcomes, with shorter 
disease-free survival and high mortality rates41.  Research suggests that PIK3CA 
mutations may also be a biomarker to predict response to radiation therapy45.  
Additionally, retrospective studies have suggested that PIK3CA mutation analysis may 
serve as a predictive marker for patients who’d benefit from adjuvant aspirin therapy, 
however, further data is needed to make testing  for this biomarker a 
recommendation39,49.  
1.10 Primary Tumor Location and Prognosis 
Numerous bodies of work have demonstrated that tumors arising in the proximal 
or right colon (i.e. cecum, ascending colon, hepatic flexure) have differing embryologic 
origins, molecular genetic signatures and prognoses compared to those arising in the 
distal or left colon (i.e. splenic flexure, descending & sigmoid colon) 39,40.  The sidedness 
of primary tumors has also been shown to be prognostically valuable, however, it would 
be an over simplification to think of the two “sides” of the colon as completely separate 
entities, as the prevalence of mutations varies within the anatomic sites on the same side 
of the colon as well as from cecum to rectum42.  
In general, colon cancer arising in the proximal colon is demographically 
associated with older, female patients and patients with familial cancers that make them 
genetically predisposed to CRC9,42,50.  Histologically, right-sided colon cancers arise from 
the serrated tumor pathway and tend to be classified as intermediate- to high-grade 
mucinous, signet-ring or undifferentiated adenocarcinoma at the time of diagnosis43, 50.  
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Additionally, they tend to have an advanced American Joint Committee on Cancer 
(AJCC) pathology stage and greater extent of invasion compared to CRC that arise 
elsewhere in the colon51.  Consequently, right-sided cancers are associated with a poor 
prognosis and a higher prevalence of recurrence and metastasis.  When metastasis occurs, 
right-sided CRC tend to metastasize to regional lymph nodes, the peritoneum and liver 50. 
From a mutation characterization perspective, colon cancer arising in the 
proximal colon tends to demonstrate hypermethylation (CIMP) with a high level of 
microsatellite instability (MSI-High) 50,52,53,.  KRAS mutations are detected in greater 
than 50% of tumors arising in the cecum and ascending colon, but this frequency 
decreases distally across the colon, with the exception being the rectum9,42.  BRAF 
V600E mutations are also associated with right-sided colon cancer and generally denote a 
poor prognosis52.  Anti-EGFR therapy is not recommended for patients with tumors 
arising in the proximal colon, because of the high frequency of RAS-family mutations30.   
Instead, anti-VEGF monoclonal antibody therapy may be the adjuant therapy of choice 
for patients with proximal colon cancers, along with standard cytotoxic agents, such as 
Folfox (5FU, leucovorin, oxaliplatin) or folfiri (5FU, leucovorin, irinotecan) 41,42.  
Colon cancer arising in the distal colon has a favorable prognosis compared to 
those arising in the proximal colon.  Macroscopically, left-sided colon cancers encircle 
the wall of the colon, and constrict and narrow the lumen as they grow52.  Consequently, 
they tend to be less advanced at the time of diagnosis, largely due to the early onset of 
clinical symptoms (i.e. blood in stool, narrow stool, obstruction) and shorter interval 
between carcinogenesis and diagnosis53.  When metastasis occurs, left-sided colon 
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cancers tend to metastasize to the lungs or bone50.  Demographically, left-sided colon 
cancers are more common in males42.   Mutationally, distal tumors are associated with 
PIK3CA mutations in the descending and sigmoid colon and KRAS mutations in the 
rectum23,42.  Additionally, distal tumors demonstrate chromosomal instability 54.  
Patient’s with left-sided colon cancer benefit from anti-EGFR monoclonal antibody 
therapies (i.e. Erbitux) in addition to cytotoxic therapy, i.e. Folfox / Folfiri, provided their 
tumor has normal, wt-KRAS32, 42, 55.  
1.11 Therapeutic Strategies for CRC 
Treatment strategies for CRC is based on the histologic grade and stage of tumors 
as well as the molecular mutations they harbor.  Colorectal cancers are pathologically 
graded and staged based on standards developed by the World Health Organization 
(WHO) and the American Joint Committee on Cancer (AJCC)23,56.  WHO grading 
categorizes colonic adenocarcinomas based on the morphology of malignant cells as well 
as their architecture or organization within the tissue.  Grade I adenocarcinomas are 
denoted as “well-differentiated” if the malignant cells microscopically resemble normal 
colonic cells with uniform, basally located nuclei, and  >95% of the malignant cells 
forming glands57, 58.  Grade II, moderately differentiated adenocarcinoma is characterized 
by a loss of nuclear polarity among the malignant cells, and 50-95% of the malignant 
cells forming glands within the tissue57, 58.  Grade III, poorly differentiated 
adenocarcinoma, is characterized by sheets of malignant cells that largely lack glandular 
architecture57, 58.    
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AJCC staging assists clinicians with determining prognosis and treatment options.  
It standardizes the reporting of the pathological features of tumors, and includes details 
regarding the depth of tumor invasion within the tissue and the extent of nodal, vascular 
and distant metastases.  AJCC staging uses TNM nomenclature, where T represents the 
depth the tumor has invaded into the wall of the colon, N denotes the number of lymph 
nodes containing metastatic tissue and M designates distant site metastasis56, 63.   Stage I 
(T1or T2) denotes localized tumors that haven’t invaded beyond the muscularis propria in 
the abdominal wall.  Stage II (T3N0, T4N0) denotes tumors that have invaded through 
the muscularis propria and penetrated the visceral peritoneum but have not invaded the 
lymph nodes. Stage III tumors invade the lymphatics and represent regional disease.  
Stage IV malignancies are those with distant metastasis to one or more organs56, 63.  
The National Comprehensive Cancer Care Network provides clinicians with 
treatment guidelines based on the resectability of the malignancy and AJCC staging 
information.  For patients with localized disease (stage I-II) surgical resection and 
observation is the standard treatment.  Some stage II malignancies (T3, T4), however, 
may carry a higher-risk for microinvasion, especially if the cells in the tumor were poorly 
differentiated or if the tumor penetrated the vascular or lymphatic system.  For this subset 
of patients, adjuvant fluoropyrimidine therapy might be administered following surgical 
resection.  Stage III-IV malignancies are often treated with surgical resection and 
chemotherapy. The specific treatment employed by clinicians is based on the tumor 
profile and comorbidities of the individual patient23.  
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Chemotherapeutic treatment options for patients with CRC typically include 5-
fluorouracil (5FU) or its oral prodrug, Capacitibine59.  Leucovorin, a compound similar to 
folic acid, is often administered with 5FU to facilitate the binding of 5FU to malignant 
cells, thereby enhancing its effect60.  5FU may also be administered in combination with 
other cytotoxic drugs, such as oxaliplatin or irinotecan.  Additionally, monoclonal anti-
body therapies that target vasoendothelial growth factor or epidermal growth factor 
receptor may be prescribed, depending on the mutational status of the patient’s tumor31.  
The mutational status of colorectal tumors assists with therapy selection and 
efficacy.  Studies have shown that patients with deficient MMR tumors respond better to 
5FU therapy compared to those with proficient DNA repair mechanisms61, 62.  
Additionally, studies have shown that patients with MMR tumors respond to checkpoint 
inhibitor therapy27, 62.  The RAS-family (NRAS and KRAS) mutational status assists with 
identifying patients who’d benefit from anti-EGFR therapy in combination with 5FU.  
Patients with RAS mutations are ineligible for anti-EGFR therapy9, 39.  
1.12 Colorectal Cancer Mutation Testing 
The key societies that provide procedural recommendations to clinical 
laboratories updated the CRC molecular testing guidelines to standardize mutational 
analyses and facilitate targeted therapy selection.  Specifically, the guidelines 
recommended that extended NRAS and KRAS mutation analysis be performed to 
determine the clinical utility of anti-EGFR therapy.  Patients with RAS mutations don’t 
benefit from anti-EGFR therapy and consequently, are ineligible for regimens that would 
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otherwise include it.  Further, BRAF V600E mutation analysis and microsatellite 
instability testing is recommended for prognostic stratification purposes.  The societies 
also considered including PIK3CA mutation panels to their testing guidelines to facilitate 
the identification of patients who might respond to aspirin therapy, but there was 
insufficient evidence to formally make this recommendation.  The authors noted, 
however, that there is a the need for additional research39 
1.13 Specific Aims of Work 
As the literature review supports, although CRC has been extensively studied, the 
prognostic and therapeutic role that individual mutations and co-mutational pathways 
play in individual chemotherapeutic response has not been fully elucidated.  In this 
population-based study, we analyzed the clinicopathological features of a retrospective 
colorectal cancer patient cohort over a seven-year span of time.  In chapter two, our 
specific aims were to examine (1) the relationships between specific clinicopathological 
variables and (2) identify variables that might facilitate the management and prognostic 
stratification of CRC patients.  
In chapter three, our specific aims were to examine (1) the frequency and 
diversity of specific mutations, 2) determine the relationships between the mutations and 
clinicopathological variables, and 3) elucidate the tumor microenvironment at various 
stages of disease to potentially facilitate the development of new companion diagnostics 
and more effective patient management strategies.  
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2 A Retrospective Population-based Study of 
Colorectal Cancer in the Upper Peninsula of Michigan 
Cancer is the second leading cause of death for Michigan residents, with 
cardiovascular disease being the first53.  The incidence rate for colorectal cancer is 
approximately 4%, with a reported 36.3 individuals per 100,000 diagnosed with colon or 
rectal cancer each year63.  This year, approximately 5,000 Michigan residents are 
expected to be diagnosed with CRC and an estimated 1,650 are expected to pass away as 
a result63.  Similarly, according to the Michigan Cancer Surveillance Program, in the 
Upper Peninsula of Michigan, an average of 36 residents per /100,000 were diagnosed 
with CRC between 2012-2016 (Figure A.1).  Fifty-eight percent of the malignancies had 
regional or distant metastatic disease at the time of diagnosis and an average of 13.3 
residents per 100,000 passed away as a result (Figure A.2)64. 
Risk factors for CRC have been well-documented and include genetic, 
environmental and lifestyle-associated factors65, 66.   Colon cancer typically affects 
people who are over the age of 50, but first-degree relatives with a history of CRC, or a 
personal history of colon polyps or ulcerative colitis increase risk and are important 
considerations when determining the appropriate age to initiate CRC screening 67.  
Lifestyle choices that contribute to an increased risk of developing colon cancer, 
including being sedentary, overweight or obese, consuming a high fat, low fiber diet with 
a high red meat content, and high-risk behaviors, like heavy alcohol and tobacco use7, 68,
3.
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Michigan is ranked in the top ten states with a high prevalence of obesity, with 1 
in every 10 adults having a BMI of >30 (obese) and 35% of residents being overweight 
(with a BMI between 25-29.9)64,69.  In the Upper Peninsula of Michigan, 67% of the 
residents have a BMI that would rank them as either overweight or obese64,69.   
Additionally, Michigan residents report the following lifestyle choices that potentially 
increase risk of cancer:  cigarette smoking (21%), alcohol use (16%), physically inactive 
lifestyle (25%)64.  Fortunately, seventy percent of respondents also reported that they 
follow the recommended CRC screening guidelines64.  
The aim of this work was to examine (1) the relationships between specific 
clinicopathological variables in CRC patients and (2) identify variables that might 
facilitate the management and prognostic stratification of CRC patients.  
2.1 Materials and Methods 
2.1.1 Study Design and Patient Population 
This retrospective, population-based study was based on a cohort of 541 patients 
who underwent surgical resection for primary, recurrent or metastatic colorectal cancer 
(CRC) between the years of 2004-2007 and 2013-2015 in a rural healthcare system in 
Michigan’s Upper Peninsula.  Patient consent forms were obtained according to 
institutional policies.  Correlative, anonymized patient demographic and clinical - 
pathological information was obtained from the Colon Cancer Tumor Registry following 
approval from the Institutional Review Board.   
From this cohort, the age, gender, specific anatomic location of the primary 
malignancy, histological grade and AJCC stage of tumor, gastroenterologists procedural 
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notes, surgical / chemotherapeutic / radiological treatment information and vital status 
was obtained.   
2.1.2 Inclusion and Exclusion Criteria 
This study included patients who underwent surgical resection for CRC and were 
≥18 years of age, with a diagnosis of primary, recurrent or metastatic adenocarcinoma of 
any histologic grade and AJCC stage (Tis-T4).  Carcinomas, neuroendocrine carcinomas, 
carcinoid tumors and lymphomas that were surgically excised from the colon were also 
included in this retrospective study.  
2.1.3 Histological Classification of Colon Cancer 
Tumors belonging to this cohort of patients were categorized based on the World 
Health Organization’s (WHO) histological grading and American Joint Committee on 
Cancer (AJCC), 7th edition, staging as denoted in the cancer registry entries.   
2.2 Results 
2.2.1 Patient Demographics 
Of the 541 cancer registry entries analyzed in this study, 56% (303) belonged to 
male patients and 44% (238) belonged to females.  The average age of the male subjects 
in this study was 66 years of age, with a range of 29 to 93 years of age.  The average age 
of the female subjects in this study was 70 years of age, with a range of 19 to 96 years of 
age (see Table A.1). 
2.2.2 Distribution of Primary Tumors 
The primary malignancies in this study arose in the following anatomic locations:  
14% cecum, 12% ascending colon, 2% hepatic flexure, 11% transverse colon, 2% splenic 
18 
flexure, 2% descending colon, 18% sigmoid colon, and 22% rectum.  Additionally, some 
of the samples in the cohort had the following “alternative” site designations:   5% right 
colon, 6% colon, 0.5% overlapping lesion, 1% left colon, 1% ileocecal valve, 1% 
appendix, and 0.2% anal-rectal junction (see Figure 2.3).  In terms of proximal vs distal 
colon, the primary cancers had the following distribution pattern:  34% proximal colon 
(cecum, ascending colon, hepatic flexure), 11% transverse colon, 24% distal colon 
(splenic flexure, descending colon, sigmoid colon), 23% rectum, 1% appendix, 6% colon, 
NOS, 0.7% ileocecal valve, 0.3% overlapping lesion, NOS.  The distribution of 
malignancies by anatomic site and patient demographics may be found in Figure A.4 and 
Table A.1.  
2.2.3 Histologic Grading and Staging by Tumor Site 
A majority of the tumors in our study were histological grade 2 adenocarcinomas, 
however, some of the tumors were only graded as “adenocarcinoma”.  Additionally, 
gastrointestinal carcinoid tumors, squamous cell carcinomas, lymphomas, and goblet cell 
tumors were included in this study.   
The AJCC staging for the samples in this study were as follows:  Stage 0 (1%; 
4/541), Stage I (20%, 109/541), Stage II (26%; 144/541), Stage III (26%; 142/541), Stage 
IV (12%; 62/541) and “unable to stage / stage x” (14%; 77 / 541).  AJCC staging wasn’t 
applicable for three non-colonic malignancies (i.e. lymphoma, Burkitt’s Lymphoma, and 
Squamous Cell Carcinoma).  Approximately 30% of the malignancies arising in the 
ileocecal valve, cecum, ascending colon, and descending colon were AJCC Stage III 
malignancies while those arising in the hepatic flexure, transverse colon, and splenic 
flexure were primarily stage II malignancies; sigmoid colon and rectum were Stage I –II.  
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In total, 48% of the patients in the cohort had localized disease (Stage I-II), with 26% 
having regional disease (Stage III) and 11% having distant metastatic disease (see Figure 
A.4).
2.2.4 Clinical Rationale for Colonoscopy Referral 
Based on data obtained from the gastroenterologist’s procedural notes, forty-eight 
percent of the patients in this cohort had colonoscopies that were classified as 
“diagnostic” because they were experiencing classical clinical symptoms of colon cancer 
including blood in stool, rectal bleeding and/or positive fecal occult blood test results or 
had polyps &/or suspicious lesions discovered during the colonoscopy procedure.  
Unfortunately, the procedural notes indicated that the reason for the original referral was 
unknown in 20% of the patients in the cohort and 16% had colonoscopies performed 
without any additional ancillary text notes. Only 3% of the patients in the study had 
colonoscopies that were designated as “screening” and, interestingly, one patient had 
their cancer detected via virtual colonoscopy (see Table A.2). 
2.2.5 Treatment 
Treatment administered to this cohort consisted of the following:  surgical 
intervention and observation (48%), Surgical and chemotherapeutic treatment (33%), 
surgical, chemotherapeutic and radiotherapy (18%), surgical intervention and 
radiotherapy (0.6%), patient declined chemotherapy (0.6%).   
2.2.6 Vital Status 
Forty-three percent (232/541) of the patients in our cohort had expired at the time 
the data was extracted from the system.  From a demographic standpoint, 57% (132/232) 
of the patients who expired were males and 43% (100/232) were females.   The primary 
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tumor location for patients who expired were as follows:  32% proximal colon (75/232), 
22% distal colon (51/232), 11% transverse colon (26/232), 21% rectum (49/232), 12% 
colon (27/232) and 2% app (4/232).  The vital status for this cohort is non-informative, as 
the cause of death was not specified in the registry data.   
2.3 Discussion 
To our knowledge, this is the first study to characterize the clinicopathological 
attributes of colon cancer in patients from the Upper Peninsula of Michigan.  In our 
cohort, there was a slightly higher percentage of male patients (56%) compared to female 
patients (44%), but this is consistent with national demographic data and correlates with 
the fact that 22% of the malignancies in our cohort arose in the rectum3.  The average age 
of male vs. female patients treated for CRC in Upper Michigan was 66 and 70 years of 
age, respectively, and is approximately 2 years younger than the national statistics3.  Our 
cohort had a higher incidence of primary tumors arising in the proximal colon (34%) 
compared to those arising in the distal colon (24%).  Interestingly, the incidence of 
proximal colon cancer was nearly 1.5x higher than the national average of 20%.  This 
finding was not artificially increased by the number of females with malignancies in the 
right colon, because the male-to-female ratio was similar (i.e. 46% males vs 54% 
females).   
Histologically, a majority of the colon cancers were histological grade 2.  From an 
AJCC staging standpoint, the colon cancers in our cohort had a favorable staging 
distribution compared to national data, with nearly half of the patients (46%) having 
tumors that were localized (grades 0-II)56.  This may be evidence of the successful 
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employment of early CRC screening programs and supports the Michigan Cancer 
Surveillance data in which 70% of Upper Michigan residents indicated they comply with 
CRC screening guidelines64.  Additionally, only twenty-six percent of the patients in our 
study had regional disease and 12% had distant metastatic disease.  Consistent with 
national trends, malignancies in the proximal colon (i.e. ileocecal valve, cecum, 
ascending colon) demonstrated more advanced disease, whereas those arising in the 
hepatic flexure and throughout the distal colon represented localized disease.  The 
descending colon was the exception with 36% of the tumors being stage III.  This largely 
supports the theory that, because of clinical symptoms, CRC in the distal colon is 
discovered and resected at earlier stages vs. those arising in the proximal colon.  
We also noted that a majority of the gastroenterologists’ procedural notes 
suggested that patients were referred for colonoscopies because of clinical symptoms 
associated with colorectal cancer.  Additionally, we noted that 53% of patients had 
suspicious lesions or polyps identified during their colonoscopic procedure.  The latter is 
counterintuitive to the CRC staging that we identified in our samples and is disconcerting 
as well.  Access to routine healthcare and individual beliefs regarding preventative 
practices may present educational opportunities for the perusal of Upper Peninsula public 
health facilities.  
2.4 Conclusion 
This study provided a thorough clinicopathological picture of colorectal 
carcinoma in Michigan’s Upper Peninsula.  Knowing that patients in the UP have 1.5x 
the incidence of CRC arising in the proximal colon provides primary care physicians with 
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the opportunity to encourage regular screening colonoscopies vs. other screening 
modalities that may not interrogate the proximal colon. This study also emphasized that 
our population is high-risk for CRC, both from a body mass index standpoint, self-
reported alcohol and tobacco product use, as supported by the prevalence of diagnostic 
colonoscopies.   
2.5 Future Opportunities 
The discovery of the predilection of proximal colon cancer in patients of rural 
Upper Michigan presents several opportunities for future initiatives.  Firstly, it is 
clinically relevant knowledge that may benefit public health clinicians and primary care 
physicians by affording them the opportunity to development strategies to aid in the early 
detection of proximal CRC malignancies.  Secondly, the knowledge gained from this 
study may benefit gastroenterologists and surgeons by alerting them to the need to 
interrogate the proximal colon when applicable. Thirdly, the findings of this work and the 
national increased incidence of CRC arising in younger adults merit the continued 
surveillance of the clinicopathologic features of CRC in Michigan’s Upper Peninsula.    
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3 Colorectal Cancer in the Upper Peninsula of 
Michigan:  A Population-based Study characterizing 
molecular mutations and clinical attributes 
An enormous amount of money and time has been invested in researching colon 
cancer, and yet the heterogeneity of the disease renders us unable to identify a biomarker 
to effectively diagnose and treat this insidious disease. Innumerable articles and clinical 
trials speak to the need for additional insight into tumor evolution and the prognostic role 
that the primary tumor’s anatomic location plays in therapeutic response36,42,70,71.   In this 
chapter, our specific aims were to (1) examine the frequency and diversity of specific 
mutations in our cohort, 2) determine the relationships between the mutations and 
clinicopathological variables, and 3) elucidate the tumor microenvironment at various 
stages of disease to potentially facilitate the development of new companion diagnostics 
and more effective patient management strategies.  
3.1 Materials and Methods 
3.1.1 Study Design and Patient Population 
A retrospective analysis was performed on 120 patients who underwent surgical 
resection for primary, recurrent or metastatic colorectal cancer between the years 2004-
2007 within a health network in Michigan’s rural Upper Peninsula.   Patient consent 
forms were obtained according to institutional policies.  Correlative, anonymized patient 
demographic and clinical- pathological information was obtained from the Colon Cancer 
Registry following approval from the Institutional Review Board.   
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In total, approximately two-thousand, five hundred zinc-formalin-fixed, paraffin-
embedded tissue blocks belonging to the patient cohort were retrieved and 230 blocks 
were selected for subsequent analysis.   These “matched” samples represented various 
stages of disease (AJCC stage Tis-T4) and included biopsies, colon polyps with high-
grade dysplasia / adenocarcinoma in-situ, resections of primary tumors, and resections 
with corresponding metastatic tissue.  Carcinomas, neuroendocrine carcinomas, carcinoid 
tumors and lymphomas excised from the colon were excluded from the analysis.  
The zinc-formalin-fixed, paraffin-embedded tissue samples were analyzed to 
identify the presence of 73 possible point mutations in the KRAS, BRAF/NRAS, and 
PIK3CA genes.  Additionally, immunohistochemical stains (i.e. MLH1/PMS2, 
MSH2/MSH6) were performed to characterize the functionality of the DNA mismatch 
repair system and PD-L1 expression (adaptive immunity) in the tumor cells.  
3.1.2 Tissue Selection and DNA extraction 
Hemotoxylin and Eosin-stained slides were retrieved and reviewed by the PI and 
a pathologist to confirm the diagnosis, histologic grade and staging of each sample. 
Optimal blocks, defined as those with ≥10% tumor content, were selected for subsequent 
mutation and IHC analysis.     
DNA was manually extracted from the archived tissue blocks using the Cobas® 
DNA Sample Preparation Kit (Roche, Indianapolis, IN).  Specifically, a five- μm section 
was obtained from each tissue block and placed in a 1.5ml PCR-safe tube, using 
protocols previously described to avoid DNA contamination72.  Next, the section was 
deparaffinized in xylene and rehydrated in 100% ETOH.  The tissue was lysed via a 
25 
protease and passed through a filter column to sequester the DNA and remove impurities. 
The nucleic acids were eluted from the filter and the genomic DNA concentration was 
determined via a Nanodrop spectrophotometer.   The concentration of the stock DNA in 
each sample was diluted to 2ng/ul, using a dilution calculation provided by the 
manufacturer, to standardize DNA content in the samples prior to the amplification and 
mutation detection.  Stock samples were stored in the -200C freezer until use.   
Also per the manufacturer’s specifications, samples initially yielding invalid 
mutation test results were retested after new dilutions of the stock DNA were prepared.  
If invalid results were acquired a second time, fresh DNA was extracted from a new 5µm 
section of FFPET tissue.    
3.1.3 K-RAS Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation 
Analysis 
“Extended” KRAS mutation analysis was performed using a “life science, 
research only” (Roche Diagnostics, Indianapolis, IN).  The assay utilized real-time PCR, 
specific base-pair primers and fluorescence resonance energy transfer (FRET) probes to 
detect mutations in the following targeted KRAS regions:  KRAS Exon 2, codons 12 and 
13 (G12A, G12C, G12D, G12R, G12S, G12V, G13A, G13C, G13D, G13R, G13S, 
G13V), KRAS Exon 3, codons 59 and 61 (A59E, A59G, A59S, A59T, Q61E, Q61Hc, 
Q61Ht, Q61K, Q61L, Q61P, Q61R), KRAS Exon 4, codons 117 and 146 (K117Nc, 
K117Nt, A146P, A146T, A146V).  A mutant control, a process control and a negative 
control were incorporated into each run to confirm the validity of the run.  Following the 
completion of the RT-PCR reaction, all data files were uploaded into the Roche web tool 
(http://oncologyresearchkits.roche.com/data-analysis) for analysis.   
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3.1.4 B-RAF Proto-oncogene (BRAF) and Neuroblastoma RAS Viral 
Oncogene Homolog (NRAS) Mutation Analysis 
“Extended” BRAF and NRAS mutation analysis was performed using a “life 
science, research only” assay developed by Roche Diagnostics (P/N: 07659962001, 
Roche Diagnostics, Indianapolis, IN).  The assay utilized real-time PCR, specific base-
pair primers and fluorescence resonance energy transfer (FRET) probes to detect the 
following mutations:  BRAF Exon 11 (G466A, G466V, G469A, G469R, G469V), BRAF 
Exon 15 (V600E, V600E2, V600D, V600K, V600R, K601E), NRAS Exon 2 (G12A, 
G12C, G12D, G12R, G12S, G12V, G13A, G13C, G13D, G13R, G13S, G13V, A18T), 
NRAS Exon 3 (Q61Ht, Q61Hc, Q61K, Q61L, Q61P, Q61R), and “other” NRAS Exon 
3and 4mutations, including A59D, K117Nc, K117Nt, A146T, A146V.   A mutant 
control, a process control and a negative control were incorporated into each run to 
confirm the validity of the run.  Following the completion of the RT-PCR reaction, all 
data files were uploaded into the Roche web tool 
(http://oncologyresearchkits.roche.com/data-analysis) for analysis.   
3.1.5 Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit 
Alpha (PIK3CA) Mutation Analysis 
“Extended” PIK3CA mutation analysis was performed using a “life science, 
research only” assay (Roche Diagnostics, Indianapolis, IN).  The assay utilized real-time 
PCR, specific base-pair primers and fluorescence resonance energy transfer (FRET) 
probes to detect the following mutations or targeted regions:  PIK3CA Exon 1 (R88Q), 
PIK3CA Exon 4 (N345K), PIK3CA Exon 7 (C420R), PIK3CA Exon 9 (E542K, E545A, 
E545D, E545G, E545K, Q546E, Q546K, Q546L, Q546R), PIK3CA Exon 20 H1047L, 
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H1047R, H1047Y, G1049R).  Following the completion of the RT-PCR reaction, the 
mutation analysis was performed by the Cobas 480z analyzer.  A mutant control, a 
process control and a negative control were incorporated into each run to confirm the 
validity of the run. 
3.1.6 Immunohistochemical Assessment of DNA Mismatch Repair Proteins 
A series of immunohistochemical stains were performed using the Benchmark 
Ultra System (Roche Ventana, Tucson, Arizona) to assess the presence or absence of 
nuclear expression in neoplastic cells for four DNA mismatch repair proteins, 
MLH1/PMS2 and MSH2/MSH6.  Four serial tissue sections (4 μm) were collected from 
each FFPET block and mounted on positively-charged microscope slides.  The first slide 
was stained with anti-MLH1 (clone M1) (Roche Ventana, Tucson, Arizona); the second 
slide was stained with anti-MSH2(clone G219-1129) (Roche / Ventana, Tucson, 
Arizona); the third slide was stained with anti-MSH6 (clone 44) (Roche / Ventana) and 
the fourth slide was stained with anti-PMS2(clone EPR3947) (Roche / Ventana,  Tucson, 
Arizona).  “Pre-qualified” colon cancer tissue (i.e. colon cancer tissue that previously 
demonstrated intact MMR proteins) served as the positive control tissue.  All slides were 
independently reviewed and scored by both the PI and a qualified pathologist to 
determine the mismatch repair protein status. 
3.1.7  Immunohistochemical Assessment of PD-L1 Expression 
Immunohistochemical assays were performed on the Benchmark Ultra 
(Roche/Ventana, Tucson, AZ) using anti-PDL-1 antibody (clone SP263) 
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(Roche/Ventana, Tucson, AZ) to evaluate PDL-1 membranous expression in tumor cells 
in cohort tissue samples.  Specifically, three (4 μm) serial sections of tissue were 
mounted on positively charged glass slides.  Hematoxylin & Eosin staining was 
performed on the first slide to confirm specimen adequacy (i.e. each section contained 
>50 viable tumor cells with associated stroma, per manufacturer guidelines).  If deemed
adequate, the second slide containing patient tissue was stained with PDL-1 (clone 
SP263) and the third with a Rabbit Monoclonal Negative Reagent Control.   Human term 
placental tissue was used for the positive control tissue.   
PDL-1 (SP263) was independently quantified by the PI and a qualified 
pathologist, using investigator-developed scoring criteria to facilitate reproducibility.  
Specifically, PDL-1 stained malignant tissue was methodically evaluated and the 
aggregation method was utilized to score percent positivity of membranous staining in 
viable tumor cells, as follows:  0-<1%, 1-9%, 10-29%, 30-49%, 50-69%, 70-89%, 90-
100%.   Staining of tumor infiltrating immune cells (IC) served as an internal control and 
was qualitatively noted but not quantified.      
3.2 Statistical Analysis 
While much of the analyses in this study were performed using descriptive statistics, R 
3.5.3 software (https://www.r-project.org/) was utilized to assess the association between 
mutational status and various clinical-pathological parameters.   
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3.3 Results 
3.3.1 Patient Demographics 
Of the 120 cancer registry entries analyzed in this study, 58% belonged to male 
patients and 42% belonged to females.  The average age of the male subjects in this 
cohort was 66 years of age, with a range of 33-89 years of age.  The average age of the 
female subjects in this study was 73 years of age, with a range of 45 - 90 years of age.   
3.3.2 Distribution of Primary Tumors by Anatomic Site 
The primary malignancies in this study were distributed across the anatomic sites 
of the colon, as follows:  13% cecum, 14% ascending colon, 5% hepatic flexure, 12% 
transverse colon, 4% splenic flexure, 2% descending colon, 19% sigmoid colon, 18% 
rectum (Figure A.5).  Additionally, some of the samples in the cohort had “alternative” 
site designations, including:   6% right colon, 4% colon, 2% ileocecal valve, 1% 
overlapping lesion, 2% left colon. From a proximal vs distal standpoint, the distribution 
of primary malignancies was as follows:  42% (51/120) proximal colon, 12% (14/120) 
transverse colon, 23% (27/120) distal colon, 18% rectum, 1% (1/120) appendix, and 4% 
(5/120) colon, NOS (Figure A.6).   
3.3.3 Histologic Grading and Staging by Anatomic Site 
The histological grade for the samples in our cohort were as follows: grade 0 
(2%), grade 1 (2%), grade 2(73%), grade 3(19%) and grade 4 (4%).  The AJCC staging 
for the samples in this study were as follows:  Stage I (29%), Stage II (35%), Stage III 
(30%), Stage IV (6%) and “unable to stage / stage x” (0.8%).  A majority of the 
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malignancies arising in the ileocecal valve, cecum, sigmoid and rectum were AJCC Stage 
III malignancies while those arising in the ascending and transverse colon flexure, splenic 
and hepatic flexures were Stage II.   
3.3.4 KRAS Mutation Status by Tumor Location 
KRAS mutations were identified in 36% of the patients in our study, with 84% of 
the mutations arising in exon 2.  Thirty-five percent of the samples with a KRAS 
mutation arose in the proximal colon (p=0.04).  Thirty-four percent of the malignancies 
with a KRAS mutation were AJCC stage I, and the mutations showed a similar 
distribution pattern across histological grades I-III.  Interestingly, 23% of the patients 
with a KRAS mutation had co-occurring mutations, with 80% of these being PIK3CA 
point mutations. 
Point mutation G12x accounted for 63% of the KRAS mutations identified in our 
cohort (Table A.4).  Malignancies with this mutation were anatomically distributed 
across the colon, and were primarily histologic grade 2, AJCC stage I-II tumors.  
Interestingly, 26% of the patients with the G12x mutation had metastatic disease, 7% had 
synchronous malignancies and 4% experienced recurrence.  Additionally, 22% of the 
patients with KRAS G12x mutation had concomitant mutations, with 27% of these being 
PIK3CA co-mutations (E545x, H1047x, Q546x).  One patient had a BRAFV600E / 
KRAS G12x  co-mutation, which reportedly occurs in 0.001% of CRC tumors 47,15. 
Twenty-one percent of the patients with a KRAS mutation had a G13x point 
mutation in Exon 2 (Table A.5).  Thirty-three percent of these had metastatic colon 
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cancer, and another patient with this mutation experienced recurrence in a different 
location in her colon two years after the diagnosis and treatment of her original 
malignancy.  The tumor cells in this patient’s original resection demonstrated PD-L1 
expression and, while PD-L1 expression was not noted in subsequent specimens, the 
KRAS G13x mutation was.  All of the samples with the KRAS G13x mutation were 
histological grade 2, with 54% being AJCC Stage III.   Of these samples, 64% arose in 
distal colon. 
Mutations in exons 4 and 3 comprised 9% and 5% of the KRAS mutations in our 
cohort, respectively.  The KRAS A146x mutation was detected in two patients, and each 
had concomitant PIK3CA mutations as well.  Two patients also had the KRAS K117x 
mutation identified in their samples.  Both of these patients had metastatic CRC, with 
malignancies arising in the distal colon.  The KRAS Q61x was identified in one patient in 
our cohort.  This patient also had a co-occurring PIK3CA mutation, C420R.  Finally, one 
patient had the A59x mutation detected in a grade 3 adenocarcinoma collected from the 
sigmoid colon (Table A.5).   
3.3.5 BRAF Mutation Status by Anatomic Site 
The BRAF V600E mutation was identified in approximately 18% of the patients 
in our cohort.  BRAF V600E mutation was associated with females (p=.001), with 
seventy-six percent of the patients with a BRAF mutation being female and twenty-four 
percent male.  Fifty-four percent of the malignancies with the BRAF V600E mutation 
arose in the proximal colon (cecum, ascending, and “right colon, NOS).  Eighteen percent 
of the BRAF V600E point mutations arose in the transverse colon, with nine percent 
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arising in the splenic flexure and sigmoid colon, respectively.  From a grading and 
staging standpoint, a majority of the tumors with BRAF mutations were histologic grade 
II or III and represented localized disease (Table A.6).  
3.3.6 NRAS Mutation Status by Anatomic Site 
Only 6% of the patients in our study had NRAS mutations detected in their tumor 
samples, with two patients having metastatic CRC and one chemoresistant cancer.  The 
average age of patients with this mutation was 67 years old, with a range of 51-84 years.  
Seventy-one percent of the NRAS mutations were in exon 3 (Q61x).  Forty-three percent 
of the NRAS mutations arose in the proximal colon, and overall, the specimens with 
NRAS mutations were histological grade II, AJCC stage I (Table A.7).   No concomitant 
mutations were identified in the patients with NRAS mutations.  
3.3.7 PIK3CA Mutation Status by Anatomic Site 
Sixteen percent of the patients in our study had a PIK3CA mutation detected in 
their tumor, with a majority of these arising in exons 9 and 20.  Patients with a PIK3CA 
mutation were, on average, 68 years of age.  Twenty one percent of the patients with a 
PIK3CA mutation had metastatic disease and sixteen percent had synchronous 
malignancies.  Overall, fifty-three percent of the samples with a PIK3CA mutation had 
one additional co-occurring mutation, and 10% had two concomitant mutations (Table 
A.8).  Interestingly, two patients in our study had co-occurring PIK3CA mutations with
an additional BRAF V600E or KRAS G12x mutation.  One of the individuals was 
initially treated for a synchronous malignancy and two years later, experienced recurrent 
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CRC.  More than half of the malignancies harboring PIK3CA mutations arose in the 
proximal colon and were categorized as histological grade 2, AJCC Stage II lesions.  
3.3.8 Concomitant Mutations by Anatomic Site 
Twenty-nine percent of the patients in our cohort had multiple mutations 
identified by IHC or PCR-based mutation analyses (Table A.9).  Of these, 43% had 
primary tumors arising in the proximal colon, with ascending colon having the greatest 
number of co-mutations.  Additionally, the frequency of concomitant mutations gradually 
decreased from the transverse colon (11%) to the rectum (3%).   
3.3.9 Immunohistochemical Analysis of DNA Mismatch Repair Proteins 
Eighty percent of the patients in our study had malignancies with intact MMR 
proteins, while 17% demonstrated a loss of two repair proteins and 3% showed the loss of 
expression of one DNA repair protein (Figures A.7-A.10 and Tables A.10 – A.12).  Of 
the patients with intact MMR proteins, 31% had metastatic disease.  Sixty-one percent of 
the tumors with intact MMR proteins belonged to males with primary malignancies 
predominantly arising in the sigmoid colon and rectum.  Conversely, a majority of the 
samples demonstrating the loss of two MMR proteins primarily belonged to female 
patients (58%) with malignancies arising in the proximal colon.  As may be expected, 
BRAF V600E mutation was often associated with deficient MMR protein expression 
(p=2.2^10-5)         
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3.3.10 Immunohistochemical Analysis of PD-L1 Expression 
Ten percent of the patients in our cohort had measurable PD-L1 expression levels 
in their tumor cells, however, expression varied among the matched patient samples 
(Figures A.11-A.12).  In general, PD-L1 expression was observed more frequently in 
tumors arising in the sigmoid and “right colon”, followed closely by those in the rectum, 
ascending colon and cecum.  PD-L1 expression levels of >30% were observed in only 
6% of our cohort, and was noted in patients with metastatic disease whose tumors arose 
in the cecum.  Tumors exhibiting 10-29% PD-L1 expression was noted in a patient whose 
malignancy arose in the appendix and in another patient who had a synchronous 
malignancy and later experienced recurrent adenocarcinoma in the proximal colon (Table 
A.13).
3.3.11 Characterization of Synchronous Malignancies 
Six patients (3 males, 3 females) in the cohort had synchronous malignancies 
(Table A.14).  The average age of the patients with synchronous malignancies was 78 
years of age for the males and 74 for the females.  The anatomic distribution of the 
malignancies was as follows:  8% ileocecal, 17% cecum, 25% ascending colon, 8% 
transverse, 17% descending colon and 25% sigmoid colon. Sixty-seven percent of the 
synchronous malignancies were histological grade II and 50% were classified as AJCC 
stage I tumors.   
Interestingly, sixty-seven percent of the synchronous malignancies had intact 
MMR proteins and 50% had identical mutations within the paired samples.  No mutations 
were identified in four of the synchronous malignancies arising in the ileocecal valve, 
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sigmoid colon, and cecum.   Paired synchronous malignancies arising in the ascending 
and transverse colon demonstrated a loss of the MLH1/PMS2 MMR proteins and the 
BRAF V600E mutation.   
Paired malignancies with divergent mutations included two samples from the 
descending colon, where one sample demonstrated <1% PD-L1 expression and a KRAS 
G12x mutation, while the other only demonstrated a PIK3CA E545x mutation.  
Additionally, one synchronous malignancy originating in the sigmoid colon showed a 
KRAS G12x mutation while the other tumor did not.  Finally, one synchronous 
malignancy originating in the ascending colon demonstrated a loss of both MLH1/PMS2 
MMR proteins, while the other only displayed a loss of MLH1.  The PIK3CA E454x 
mutation was identified in both of these paired malignancies.   
3.3.12 Characterization of Recurring Malignancies 
Three female patients in our study experienced recurrent colon cancer within two 
years post-surgical excision of their primary malignancy.  Another patient initially had 
synchronous malignancies and later developed recurrent cancer. Fifty percent of these 
tumors arose in the rectum, with the remaining malignancies arising in the “right colon, 
NOS” (38%) and sigmoid colon (12%).  Fifty percent of the tumors were histologically a 
grade 2, with a majority being AJCC stage II (Table A.15).   
Interestingly, the mutations in the recurrent malignancies largely resembled those 
in the original primary cancer. For instance, for one patient, the KRAS G12x mutation 
was identified in both the primary and recurring malignancy arising in the rectum.  
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Another patient had synchronous tumors arising in the “right colon” that exhibited a loss 
of both MLH/PMS2 MMR proteins, the BRAF V600E mutation and PIK3CA mutations 
H1047x and E545x.  Additionally, both demonstrated PD-L1 expression in the tumor 
cells, with 10-29% expression in one and 1-9% expression in the other.  Two years later, 
the recurrent cancer in the biopsy and resection demonstrated a similar loss of MMR 
proteins, PD-L1 expression levels and BRAF V600E mutation. The PIK3CA mutations, 
however, were not detected in the recurrent malignancy.  Lastly, a malignancy that arose 
in the sigmoid colon displayed 1-9% expression of PD-L1 and the KRAS G13x mutation.  
The recurrent cancers in the rectum did not express PD-L1 but the KRAS G13x mutation 
was identified in each. 
3.3.13 Characterization of Chemoresistant Malignancies 
Approximately 7% (8/120) patients in this study had malignancies that were 
presumed to be chemoresistent, based on multiple courses of cytotoxic therapy 
administered over an extended amount of time and treatment notes (Table A.16).  
Chemoresistence was noted evenly between males and females in this category (4/8 or 
50% each).  The average age for the males in this category was 51 years of age (range 
from 46-53 years of age) and 62 for females, with a range of 45-70 years of age.  The 
anatomic location of primary malignancies was as follows: 25% (2/8) rectum, 12.5% 
(1/8) for each of the following sources: Overlapping lesion, Ascending, Transverse, 
Sigmoid, Colon, and Right colon.  Mutations characterized in this subset of patients / 
samples included the following: KRAS G13x was detected in one patient’s sample 
(sigmoid), KRAS G12x was detected in one patient’s sample (transverse), KRAS 146x 
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and PIK3CA E545x was detected in one patient sample (ascending colon), NRAS Q61x 
and MMR repair protein markers (loss of PMS2) was detected in one patient sample 
(right colon).  Interestingly, we were unable to identify mutations in no mutations in 
samples belonging to 50% of the patients.  
In terms of histologic grade and AJCC staging of chemoresistent tumors, 75% 
(6/8) of the patients had malignancies that were histological grade 2 and 25% (2/8) of the 
patients had malignancies that were histological grade 3.  Fifty percent (4/8) of the 
patients had malignancies that were Stage III (3@ T3N1M0, 1 @ T2N2M0), 38% (3/8) 
had malignancies that were Stage II (3@ T3N0M0) and 12% (1/8) had a malignancy that 
was Stage IV (T3N2M1). 
3.3.14 Characterization of Malignancies That Mutations Weren’t Detected In 
Twenty-two percent of the patients in our cohort had malignancies that we were 
unable to identify mutations in (Table A.17).  Of these, 26% were from patients with 
metastatic CRC.  Seventy-eight of these samples belonged to male patients, with an 
average age of 68 years of age.  These tumors were distributed across the following 
anatomic sites: 44% rectum, 18% sigmoid, 11% hepatic flexure, 7% transverse, 4% 
ascending, 7% cecum, 4% overlapping lesion, 4% right colon.   Eighty-one percent of 
these malignancies were histological grade 2, with a majority being AJCC stage I or II. 
3.3.15 Characterization of Patients with Cancer-related Cause of Death 
Thirty-seven percent (44/120) of the patients in our cohort passed away from 
cancer-related causes, with 48% (21/44) male and 52% (23/44) female.   Thirty-four 
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percent of these patients (15/44) were initially diagnosed with mCRC, whereas 57% 
(25/44) originally were diagnosed with localized cancer or had synchronous &/or 
recurrent cancer (9%, 4/44).  Anatomically, the tumors distributed as follows:  cecum 
16% (7/44), ascending 9% (4/44), hepatic flexure 7% (3/44) , transverse 14% (6/44), 
splenic flexure 5% (2/44), descending 7% (3/44), sigmoid 11% (5/44), rectum 18% 
(8/44), overlapping lesion 2% (1/44), ileocecal valve 2% (1/44), right colon 7% (3/44), 
and colon 2% (1/44).  In terms of sidedness of the colon, 43% (19/44) of the tumors in 
this category arose in the proximal colon, 23% (10/44) arose in the distal colon, 14% 
(6/44) were located in the transverse colon and 18% (8/44) were in the rectum (Table 
A.18).
Of the patients who originally had metastatic disease and passed away due to 
cancer-related causes, 53% were female (8/15) and 46% were male (7/15), with an 
average age of 71 years and 67 years at the time of diagnosis, respectively. Interestingly, 
although these patients had mCRC, 33% had tumors that only demonstrated regional 
disease, with AJCC staging T3N1M0 (stage III).  The tumors in this subgroup were 
comprised of the following mutations:  BRAF V600E (20%), KRAS G12x (27%), PDL-1 
expression (7%), PIK3CA G1049R (7%), PIK3CA N345K (7%), NRAS Q61x (7%), 
KRAS A146x (7%), KRAS K117x (7%).  Interestingly, 27% (4/15) of the tumors in this 
subset had no mutations identified.  
Of the patients who originally had localized disease, 55% were female (6/11) and 
45% were male (5/11), with an average age of 75 years and 65 years at the time of 
diagnosis, respectively. Twenty-seven percent (3/11) of the patients in this subset went on 
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to develop secondary malignancies in the lung, pelvis or small intestine.  The primary 
tumors primarily arose in the transverse, ascending colon and hepatic flexure, but tumors 
were also noted in the cecum, sigmoid.  Forty-four percent of the tumors were AJCC 
stage II (T3N0M0).  The tumors from this subgroup were comprised of the following 
mutations:  45% BRAF V600E, 27% MMR showing loss of MLH1/PMS2, 27% PDL-1 
expression in the tumor cells, 18% PIK3CA E545x, and 9%  had a PIK3CA H1047x or 
KRAS G12x mutation.  Interestingly, 27% (3/11) of the tumors in this subset had no 
mutations identified.  
The sample size (5/44) was very small for the patients who originally had 
refractory CRC or synchronous malignancies and died from cancer-related causes.  The 
13 samples for this subset were predominately grade 2 lesions with AJCC staging ranging 
from stage I -III.  Interestingly, many of the recurrent malignancies demonstrated a 
similar mutation pattern compared to the original cancer. 
3.4 Discussion: 
Although numerous studies have focused on colorectal cancer, to our knowledge, 
this is the first study to characterize the molecular mutations and clinicopathological 
attributes of colon cancer in patients from the Upper Peninsula of Michigan.  Based on 
our data, the Upper Peninsula has a higher incidence of primary CRC arising in the 
proximal colon compared to percentages published in the literature73.   This finding 
doesn’t appear to be biased by the composition of our cohort, as there was a higher 
percentage of male patients (58%) vs female patients (42%) in our study.  
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The prevalence of KRAS, NRAS, BRAF, and PIK3CA mutations in our cohort 
concurred with the frequencies published in the literature, as did the MMR / MSI status.  
Although not statistically significant, we observed  KRAS G12x and G13x mutations in 
mCRC in our study, which anecdotally correlates with the poor outcomes described by 
other bodies of work39,34,35.   Additionally, PIK3CA mutations, most notably the H1047x 
and E545x, were associated with a poor prognosis.  Forty-two percent (8/19) of the 
patients with a PIK3CA mutation died from cancer-related causes and most had tumors 
arising in the transverse, descending and sigmoid colon.  We also noted that more than 
half of the tumors with a PIK3CA mutation had a concomitant mutation.  These 
observations are consistent with those described in the literature74, 75, 36.  
We observed a relationship between BRAF and MMR / MSI, with a higher 
incidence of MMR in female patients (p= 0.02 and p=0.001, respectively) with 
malignancies arising in the ascending colon, as also described in the literature76.  
Additionally, as Rosenbaum, et al also noted, we observed a relationship between tumors 
exhibiting PD-L1 expression and BRAF V600E mutation 24.  Further, our study 
demonstrated a concomitant KRAS and BRAF mutation which conflicts with the theory 
that these two mutations occur mutually exclusive of each other71.  This phenomenon, 
albeit extremely rare, had been observed by other researchers77, 78.  
Although only 6% of the patients in our cohort had an NRAS mutation, the NRAS 
Q61x was the most frequently identified NRAS mutation and was associated with tumors 
arising throughout the colon.  Seventy-one percent of all of the NRAS mutations in this 
41 
cohort were associated with localized disease (Stage I-II), as noted in previous works by 
Takane, et al and Ahmed, et al5,35. 
We had the opportunity to characterize synchronous malignancies belonging to 6 
individuals in our cohort.  Interesting, the male-to-female ratio was even and there was a 
predilection for synchronous tumors to arise in the proximal colon (i.e. ileocecal, cecum 
and ascending).  While the remaining tumors arose in the distal (descending and sigmoid) 
and transverse colon, 42% and 8%, respectively, none were associated with the rectum.  
We observed that a majority of these tumors had intact MMR proteins and the paired 
synchronous samples that had identical mutations arose in the ascending and transverse 
colon whereas those with divert mutations arose in the descending and sigmoid colon.  
Although synchronous cancers may be found throughout the colon, our findings correlate 
with work performed by Lam et al, from the observation that synchronous cancers were 
primarily noted in the proximal colon75.  We differed in our gender observations and the 
predilection for MMR, but this discrepancy is likely due to our small sample size.  
We also had a subset of patients that experienced refractory malignancies.  This 
portion of the cohort was too small to make anatomic site comparisons, but we did notice 
mutation patterns in the matched samples.  Specifically, we noticed that the synchronous 
malignancies had identical or similar mutation patterns in the matched samples.  This 
observation was also noted in patients who experienced recurrent CRC after having 
synchronous malignancies.  We also noticed that several of the samples had deficient 
MMR, but this isn’t generalizable due to our small sample size. 
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From a clinicopathological perspective, the chemoresistent patients (7%) in our 
cohort were as challenging to characterize as they likely were to treat.  We observed a 
RAS family mutation in half of these patients, with no mutations identified in the 
remaining 50%.  Seventy-five percent had tumors that were histological grade 2 and 50% 
had regional lymphatic invasion.    Half of this sample set received surgical, 
chemotherapeutic and radiotherapy and the other 50% received surgical, 
chemotherapeutic therapies followed by observation.   Similarly, we observed a subset of 
malignancies that we were unable to identify mutations in.  Interestingly, a majority of 
these tumors belonged to males, with 44% of these tumors originating in the rectum.  A 
majority of these tumors were grade 2 and represented localized disease. Together, we 
believe these findings correlate with the heterogeneity of CRC and the treatment 
challenges it poses23, 79.   
3.5 Limitations of the Study 
Although there were many strengths of this study, there were also numerous 
limitations as well. We had a relatively small sample size and didn’t have access to a 
detailed clinical history for the patients in our cohort.  Therefore, we don’t know if the 
patients in our study had a history of diabetes, inflammatory bowel disease or previous 
cancer.  We also don’t know our cohort’s genetic background, ethnicity, dietary habits, 
and exposure to tobacco, alcohol, or survival details from diagnosis to death.  We didn’t 
have access to information regarding the ischemia time post specimen collection or about 
the storage conditions of our tissue blocks.  Because we wanted to correlate the frequency 
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and diversity of mutations with clinicopathological data, there also may be some 
selection bias associated with our study.    
3.6 Conclusion 
In this novel population-based study, we comprehensively analyzed mutations in 
the MAPK, PIK3CA, and DNA mismatch repair pathways and correlated our findings 
with the clinicopathological attributes belonging to the patients in our cohort.  From a 
primary tumor location perspective, we noted that there is a predilection for primary CRC 
to arise in the proximal colon of patients in the Upper Peninsula of Michigan.  From a 
mutation status and patient outcomes perspective, although anecdotal due to the small 
size of our cohort, we observed PIK3CA (H1047x, E545x) and KRAS (G12x, G13x) 
mutations to be associated with a poor prognosis, including cancer-related death.  
We also had the opportunity to analyze mutations at various stages of disease in 
matched samples, including biopsies, resections, metastatic disease and synchronous and 
recurrent malignancies.  We largely observed an analogous mutational status among 
matched patient samples which may be clinically informative regarding treatment 
strategies for refractory malignancies.  In total, we believe our work will inspire future 
patient and clinician educational initiatives and research endeavors.  Additionally, this 
work may facilitate the development of future companion diagnostic tests and improved 
patient management strategies.   
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3.7 Future Opportunities 
This study may provide the catalyst for several future studies.   The increased 
number of CRC arising in younger patients, the predominance of primary tumors arising 
in the proximal colon and the observation that specific KRAS and PIK3CA mutations 
may be associated with an inferior patient prognosis provide justification and will 
hopefully spark additional prospective research endeavors.   Additionally, the subset of 
malignancies with mutations that precluded detection in our study present a unique 
challenge and research opportunity for future work.  
45 
4 Reference List 
1. Key Statistics for Colorectal Cancer. https://www.cancer.org/cancer/colon-rectal-
cancer/about/key-statistics.html.
2. Cancer of the Colon and Rectum - Cancer Stat Facts. SEER
https://seer.cancer.gov/statfacts/html/colorect.html.
3. Street, W. Colorectal Cancer Facts & Figures 2017-2019. 40.
4. The Cancer Genome Atlas Network. Comprehensive molecular characterization of
human colon and rectal cancer. Nature 487, 330–337 (2012).
5. Takane, K. et al. DNA methylation epigenotype and clinical features of NRAS‐
mutation(+) colorectal cancer. Cancer Med 6, 1023–1035 (2017).
6. Komiya, Y. & Habas, R. Wnt signal transduction pathways. Organogenesis 4, 68–75
(2008).
7. Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. Oncogene 36, 1461–
1473 (2017).
8. Farooqi, A. A., de la Roche, M., Djamgoz, M. B. A. & Siddik, Z. H. Overview of the
oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Seminars in
Cancer Biology 58, 65–79 (2019).
46 
9. Morkel, M., Riemer, P., Bläker, H. & Sers, C. Similar but different: distinct roles for
KRAS and BRAF oncogenes in colorectal cancer development and therapy
resistance. Oncotarget 6, 20785–20800 (2015).
10. Cathomas, G. PIK3CA in Colorectal Cancer. Front Oncol 4, (2014).
11. Wicha, M. S., Liu, S. & Dontu, G. Cancer Stem Cells: An Old Idea—A Paradigm
Shift. Cancer Res 66, 1883–1890 (2006).
12. Vaiopoulos, A. G., Kostakis, I. D., Koutsilieris, M. & Papavassiliou, A. G. Colorectal
Cancer Stem Cells. STEM CELLS 30, 363–371 (2012).
13. Consensus molecular subtypes and the evolution of precision medicine in colorectal
cancer - 5.10.1038@nrc.2016.126.pdf.
14. Bae, J. M., Kim, J. H. & Kang, G. H. Molecular Subtypes of Colorectal Cancer and
Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia
Pathway. Archives of Pathology & Laboratory Medicine 140, 406–412 (2016).
15. Müller, M. F., Ibrahim, A. E. K. & Arends, M. J. Molecular pathological
classification of colorectal cancer. Virchows Arch 469, 125–134 (2016).
16. Ciccia, A. & Elledge, S. J. The DNA Damage Response: Making It Safe to Play with
Knives. Molecular Cell 40, 179–204 (2010).
17. Lee, M. S., Menter, D. G. & Kopetz, S. Right vs Left Colon Cancer Biology:
Integrating Consensus Molecular Subtypes. JNCCN 15, 411–419 (2017).
47 
18. Mojarad, E. N., Kuppen, P. J., Aghdaei, H. A. & Zali, M. R. The CpG island
methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench
6, 120–128 (2013).
19. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell
144, 646–674 (2011).
20. Dallas, N. A. et al. Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth factor-I receptor
inhibition. Cancer Res. 69, 1951–1957 (2009).
21. Zeuner, A., Todaro, M., Stassi, G. & De Maria, R. Colorectal Cancer Stem Cells:
From the Crypt to the Clinic. Cell Stem Cell 15, 692–705 (2014).
22. Danielsen, H. E. et al. Prognostic markers for colorectal cancer: estimating ploidy
and stroma. Ann Oncol 29, 616–623 (2018).
23. Fotheringham, S., Mozolowski, G. A., Murray, E. M. A. & Kerr, D. J. Challenges
and solutions in patient treatment strategies for stage II colon cancer. Gastroenterol
Rep (Oxf) 7, 151–161 (2019).
24. PD-L1 expression in colorectal cancer is associated with microsatellite instability,
BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- illiad.dll.
48 
25. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1)
expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer -
art%3A10.1186%2Fs12943-016-0539-x.pdf.
26. Li, Y. et al. The Prognostic and Clinicopathological Roles of PD-L1 Expression in
Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Pharmacol 10,
(2019).
27. Korehisa, S. et al. Clinical significance of programmed cell death-ligand 1 expression
and the immune microenvironment at the invasive front of colorectal cancers with
high microsatellite instability. International Journal of Cancer 142, 822–832 (2018).
28. Nojadeh, J. N., Behrouz Sharif, S. & Sakhinia, E. Microsatellite instability in
colorectal cancer. EXCLI J 17, 159–168 (2018).
29. Gragg, H., Harfe, B. D. & Jinks-Robertson, S. Base composition of mononucleotide
runs affects DNA polymerase slippage and removal of frameshift intermediates by
mismatch repair in Saccharomyces cerevisiae. Mol. Cell. Biol. 22, 8756–8762 (2002).
30. Patel, M. et al. The relationship between right-sided tumour location, tumour
microenvironment, systemic inflammation, adjuvant therapy and survival in patients
undergoing surgery for colon and rectal cancer. Br J Cancer 118, 705–712 (2018).
31. Benson, A. B. et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc Netw 15, 370–398 (2017).
49 
32. Oikonomou, E., Koustas, E., Goulielmaki, M. & Pintzas, A. BRAF vs RAS
oncogenes: are mutations of the same pathway equal? differential signalling and
therapeutic implications. Oncotarget 5, 11752–11777 (2014).
33. Reference, G. H. KRAS gene. Genetics Home Reference
https://ghr.nlm.nih.gov/gene/KRAS.
34. Haigis, K. M. KRAS Alleles: The Devil Is In The Detail. Trends Cancer 3, 686–697
(2017).
35. Ahmed, S. et al. Primary Tumor Location and Survival in the General Population
With Metastatic Colorectal Cancer. Clin Colorectal Cancer 17, e201–e206 (2018).
36. Reggiani Bonetti, L. et al. Clinical Impact and Prognostic Role of
KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer. Disease Markers
https://www.hindawi.com/journals/dm/2018/2959801/ (2018)
doi:10.1155/2018/2959801.
37. Phipps, A. I. et al. KRAS-mutation status in relation to colorectal cancer survival: the
joint impact of correlated tumour markers. Br J Cancer 108, 1757–1764 (2013).
38. pubmeddev & al, A.-M. F., et. Structural differences between valine-12 and
aspartate-12 Ras proteins may modify carcinoma aggression. - PubMed - NCBI.
https://www.ncbi.nlm.nih.gov/pubmed/10398103.
39. Molecular Biomarkers for the Evaluation of Colorectal Cancer - pdf.
50 
40. Lam, A. K.-Y., Chan, S. S.-Y. & Leung, M. Synchronous colorectal cancer: Clinical,
pathological and molecular implications. World J Gastroenterol 20, 6815–6820
(2014).
41. Dvorak, K. et al. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody:
impact of pre-analytical conditions and concordance with DNA sequencing in
colorectal and papillary thyroid carcinoma. Pathology 46, 509–517 (2014).
42. Loree, J. M. et al. Classifying colorectal cancer by tumor location rather than
sidedness highlights a continuum in mutation profiles and Consensus Molecular
Subtypes. Clin Cancer Res 24, 1062–1072 (2018).
43. Schell, M. J. et al. A multigene mutation classification of 468 colorectal cancers
reveals a prognostic role for APC. Nat Commun 7, (2016).
44. Understanding BRAF-Mutant Colorectal Cancer. ASCO Annual Meeting
https://am.asco.org/daily-news/understanding-braf-mutant-colorectal-cancer (2016).
45. Hamada, T., Nowak, J. A. & Ogino, S. PIK3CA mutation and colorectal cancer
precision medicine. Oncotarget 8, 22305–22306 (2017).
46. Reference, G. H. PIK3CA gene. Genetics Home Reference
https://ghr.nlm.nih.gov/gene/PIK3CA.
47. Nisa, L. et al. PIK3CA hotspot mutations differentially impact responses to MET
targeting in MET-driven and non-driven preclinical cancer models. Mol Cancer 16,
(2017).
51 
48. Wang, Q. et al. PIK3CA mutations confer resistance to first-line chemotherapy in
colorectal cancer. Cell Death Dis 9, 1–11 (2018).
49. PIK3CA in colorectal cancer. ResearchGate
https://www.researchgate.net/publication/260761852_PIK3CA_in_colorectal_cancer.
50. Lee, M. S., Menter, D. G. & Kopetz, S. Right Versus Left Colon Cancer Biology:
Integrating the Consensus Molecular Subtypes. J Natl Compr Canc Netw 15, 411–
419 (2017).
51. Meguid, R. A., Slidell, M. B., Wolfgang, C. L., Chang, D. C. & Ahuja, N. Is There a
Difference in Survival Between Right-Versus Left-Sided Colon Cancers? Ann Surg
Oncol 15, 2388–2394 (2008).
52. Lee, M. S. et al. Association of primary (1°) site and molecular features with
progression-free survival (PFS) and overall survival (OS) of metastatic colorectal
cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. J. Clin.
Oncol. 34, (2016).
53. Mik, M., Berut, M., Dziki, L., Trzcinski, R. & Dziki, A. Right- and left-sided colon
cancer – clinical and pathological differences of the disease entity in one organ.
Archives of Medical Science : AMS 13, 157 (2017).
54. New Studies Offer Insight Into Implications of Left- Versus Right-Sided Primary




55. Colorectal Cancer Survival Linked to Primary Tumor Location. National Cancer
Institute https://www.cancer.gov/news-events/cancer-currents-blog/2016/colorectal-
survival-location.
56. Colorectal Cancer Stages. https://www.cancer.org/cancer/colon-rectal-
cancer/detection-diagnosis-staging/staged.html.
57. Fleming, M., Ravula, S., Tatishchev, S. F. & Wang, H. L. Colorectal carcinoma:
Pathologic aspects. J Gastrointest Oncol 3, 153–173 (2012).
58. Adenocarcinoma of colon.
http://www.pathologyoutlines.com/topic/colontumoradenocarcinoma.html.
59. Chemotherapy for Colorectal Cancer. WebMD https://www.webmd.com/colorectal-
cancer/chemotherapy.
60. Leucovorin - Chemotheray Drugs - Chemocare.
http://chemocare.com/chemotherapy/drug-info/Leucovorin.aspx.
61. Zaanan, A. et al. Role of Deficient DNA Mismatch Repair Status in Patients With
Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled
Analysis From 2 Randomized Clinical Trials. JAMA Oncol 4, 379–383 (2018).
53 
62. Oliveira, A. F., Bretes, L. & Furtado, I. Review of PD-1/PD-L1 Inhibitors in
Metastatic dMMR/MSI-H Colorectal Cancer. Front Oncol 9, 396 (2019).
63. USCS Data Visualizations. https://gis.cdc.gov/grasp/USCS/DataViz.html.
64. Olsabeck, T. Michigan Cancer Atlas 2019. 60.
65. Durko, L. & Malecka-Panas, E. Lifestyle Modifications and Colorectal Cancer. Curr
Colorectal Cancer Rep 10, 45–54 (2014).
66. Johnson, C. M. et al. Meta-analyses of Colorectal Cancer Risk Factors. Cancer
Causes Control 24, 1207–1222 (2013).
67. What Are the Risk Factors for Colorectal Cancer? | CDC.
https://www.cdc.gov/cancer/colorectal/basic_info/risk_factors.htm (2019).
68. Colon cancer - Symptoms and causes. Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/colon-cancer/symptoms-causes/syc-
20353669.
69. Mack, J. Almost a third of Michigan adults are obese; see percent in your county.
mlive https://www.mlive.com/news/2019/04/almost-a-third-of-michigan-adults-are-
obese-see-percent-in-your-county.html (2019).
70. Yu, Y. et al. The long-term survival characteristics of a cohort of colorectal cancer
patients and baseline variables associated with survival outcomes with or without
time-varying effects. BMC Medicine 17, 150 (2019).
54 
71. Jauhri, M. et al. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS,
TP53, and APC mutations in Indian colorectal cancer patients: Next-generation
sequencing–based cohort study. Tumour Biol. 39, 1010428317692265 (2017).
72. Hunt, J. L. & Finkelstein, S. D. Microdissection Techniques for Molecular Testing in
Surgical Pathology. Archives of Pathology & Laboratory Medicine 128, 1372–1378
(2004).
73. Abstracting Keys | SEER Training.
https://training.seer.cancer.gov/colorectal/abstract-code-stage/keys.html.
74. Rosty, C. et al. PIK3CA Activating Mutation in Colorectal Carcinoma: Associations
with Molecular Features and Survival. PLOS ONE 8, e65479 (2013).
75. Catasus, L., Gallardo, A., Cuatrecasas, M. & Prat, J. PIK3CA mutations in the kinase
domain (exon 20) of uterine endometrial adenocarcinomas are associated with
adverse prognostic parameters. Mod Pathol 21, 131–139 (2008).
76. Kim, S.-E. et al. Sex- and gender-specific disparities in colorectal cancer risk. World
J Gastroenterol 21, 5167–5175 (2015).
77. Larki, P. et al. Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A
Case Report Supporting The Concept of Tumoral Heterogeneity. Cell J 19, 113–117
(2017).
55 
78. Liu, J. et al. Predictive and Prognostic Implications of Mutation Profiling and
Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma.
Gastroenterol Res Pract 2018, 4585802 (2018).
79. Sartore-Bianchi, A., Loupakis, F., Argilés, G. & Prager, G. W. Challenging
chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and
from the laboratory. Ann Oncol 27, 1456–1466 (2016).
56 
A Figures and Tables 
A.1 Incidence of Colorectal Cancer in the Upper Peninsula 
of Michigan. 
A.2 Percent of Upper Michigan Residents by County 
Diagnosed with Advanced Disease.  
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A.3 Patient Demographics & Anatomic Distribution of 























Cecum 74 14% 31 42% 69 43 58% 73 
Ascending 
Colon 
68 12% 29 43% 70 39 57% 74 
Hepatic 
flexure 
11 2% 9 82% 71 2 18% 65 
Transverse 
Colon 
58 11% 35 60% 69 23 40% 72 
Splenic 
Flexure 
13 2% 7 54% 65 6 46% 67 
Descending 
Colon 
14 3% 4 29% 69 10 71% 74 
Sigmoid 
Colon 
99 18% 65 66% 62 34 34% 64 
Rectum 121 22% 77 64% 67 44 36% 67 
Colon, NOS 34 22% 21 62% 66 13 38% 65 
Left colon 4 1% 2 50% 64 2 50% 61 
Right colon 28 5% 14 50% 68 14 50% 76 
Ileocecal 
valve 
6 1% 3 50% 73 3 50% 74 
Appendix 7 1% 5 71% 60 2 29% 40 
Overlapping 
Lesion 
 3 .05% 1 33% 56 2 67% 77 
Anal-rectal 
junction 
1 0.1% 0 0 1 100% 51 
Table A.1.  Patient Demographics and Anatomic Distribution of Primary 
Colorectal Malignancies.   
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A.4 Anatomic Distribution of Primary Colorectal Cancer in 
Patient Cohort. 
 
Figure A.3.  Anatomic Distribution of Primary Colorectal Cancer in 
Patient Cohort.  
Image used with permission of Mayo Foundation for Medical Education and Research, all 
rights reserved.  
59 
A.5 AJCC (7th ed) Staging by Anatomic Site of Primary 
Malignancy. 
Figure A.4.  AJCC Staging By Anatomic Site of Primary Malignancy in 
Patient Cohort.  A majority of the malignancies arising in the proximal colon 
represented regional disease, with more localized disease noted from the hepatic 
flexure to the splenic flexure.  Additionally, a majority of the malignancies in the 
distal colon and rectum represented localized disease, with the exception being the 
descending colon.  
Image used with permission of Mayo Foundation for Medical Education and Research, all rights 
reserved.  
60 
A.6 Classification of Colonoscopies and Mechanism for 
Detection of CRC for Patients In This Cohort. 
 
Method of Diagnosis for Cohort 
Colonoscopy, NOS 88 16% 
Screening Colonoscopy 13 2% 
Screening Colonoscopy with Biopsy 7 1% 
Diagnostic Colonoscopy 132 24% 
Diagnostic Colonoscopy with Biopsy 130 24% 
EGD and Colonoscopy 14 2% 
EGD and Colonoscopy with Biopsies 25 5% 
Sigmoidoscopy 5 1% 
Abnormal CT of Abdomen 1 0.2% 
Bilateral Pulmonary Nodules and 
Large Bowel Obstruction 
1 0.2% 
Abnormal Virtual Colonoscopy 1 0.2% 
CT-guided Biopsy 1 0.2% 
Colon and Liver Biopsy 1 0.2% 
Exploratory Laparotomy 7 1% 
Appendix, omentum, peritoneum 
biopsy 
1 0.2% 
Patient unable to tolerate prep 3 0.5% 
Colonoscopy unsuccessful, NOS 1 0.2% 
Unknown / None 110 20% 
Table A.2.  Classification of Colonoscopies and Mechanism 
for Detection of CRC For Patients in this Cohort.  
Gastroenterologist procedural notes and cancer registry data 
classified the colonoscopies performed on patients in this study 
and provided insight regarding the mode of diagnosis for the 
CRC samples analyzed in this study. 
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A.7 Distribution of Anatomic Site of Primary Malignancy in 
Patient Cohort. 
Figure A.5.  Distribution of Anatomic Site of Primary Malignancy in Patient 
Cohort.   The primary malignancies belonging to patients in this cohort were 
distributed across the anatomic sites in the colon. 
Image used with permission of Mayo Foundation for Medical Education and Research, all rights 
reserved.  
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A.8 Distribution of Primary Malignancies in the Proximal vs. 
Distal Colon for Patient Cohort. 
 
 
Figure A.6.  Distribution of Primary Malignancies in the Proximal vs. Distal 
Colon for Patient Cohort.   A majority of the malignancies belonging to 
patients in this cohort arose in the proximal colon.  While patients and matched 
samples were randomly selected for mutation studies, the distribution of primary 
malignancies is representative of the larger cohort’s retrospective review. 
Image used with permission of Mayo Foundation for Medical Education and Research, all rights 
reserved.  
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Table A.3.  AJCC Staging by Primary 
Site for 120 Patient Cohort.   
For this subset of patients, a majority of 
the malignancies arising in the the cecum, 
sigmoid colon and rectum represented 
regional disease.  Conversely, those 
arising in the ascending and transverse 
colon represented localized disease.   
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A.10 Correlation of KRAS G12x Targeted Region Mutations








Source       Gender      Age 
WHO Grade AJCC 
Staging Cause of Death 
G12x 
Cecum Male 70 Grade 2 T3N2M1 
Stage IV 
Cancer-related 
Rectum Male 35 Grade 2 T3N1M0 
Stage III 
Unknown 
Ascending Male 50 Grade 2 T2N1M0 
Stage III 
Not cancer-related 
Transverse Female 66 Grade 2 T3N1M0 
Stage III 
Cancer-related 
Sigmoid Female 74 Grade 2 T4N1Mx 
Stage III 
Cancer-related 
Transverse Female 66 Grade 2 T3N1M1 
Stage IV 
Cancer-related 
Ascending Female 90 Grade 3 T3N2M0 
Stage III 
Unknown 
Ascending Female 48 Grade 2 T3N0M0 
Stage II 
Not applicable 
Rectum Female 83 Grade 2 T3N0M0 
Stage II 
Not applicable 
Colon Female 73 Grade 2 T1N0M0 
Stage I 
Unknown 
Sigmoid Male 68 Grade 3 T1N0M0 
Stage I 
Cancer-related 
Ascending Female 83 Grade 2 T2N0M0 
Stage I 
Not cancer-related 
Ascending Male 67 Grade 2 T2N0M0 
Stage I 
Unknown 
Transverse Female 69 Grade 2 T3N0M0 
Stage II 
Not cancer-related 
Transverse Female 76 Grade 4 T3N0M0 
Stage II 
Cancer-related 
Colon, NOS Male 75 Grade 2 T3N0M0 
Stage II 
Not cancer-related 
Sigmoid Male 64 Grade 2 T3N0M0 
Stage II 
Unknown 
Cecum Female 55 Grade 2 T2N0M0 
Stage I 
Not applicable 
Table A.4.  Correlation of KRAS G12x Targeted Region Mutations with 
Clinicopathological Data for the Patient Cohort.    
KRAS G12x was the most common KRAS mutation identified in our cohort.  From a 
clinico-pathological perspective, this mutation was observed in a higher frequency in 
primary tumors arising in the proximal colon.  The KRAS G12x mutation was primarily 
identified in  Grade 2, Stage II adenocarcinoma. 
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Cause of Death 
G12x 
Rectum Male 72 Grade 2 T1N0M0 
Stage I 
unknown 
Cecum Male 62 Grade 3 T3N0M0 
Stage II 
Unknown 
Cecum Male 57 Grade 3 T3N0M0 
Stage II 
Unknown 





Male 89 Grade 2 T4N0M0 
Stage II 
Cancer-related 
















Male 78 Grade 2 T4N2M0 
Stage III 
Cancer-related 
Sigmoid Female 74 Grade 3 T2N0Mx 
Stage I 
Unknown 
Table A.4.  Correlation of KRAS G12x Targeted Region Mutations with 
Clinicopathological Data for the Patient Cohort (continued)   
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A.12 Correlation of KRAS G13x Targeted Region Mutations










Cause of Death 
G13x Hepatic 
flexure 
Female 63 Grade 2 T4N1M0 
Stage III 
Not applicable 
Sigmoid Female 45 Grade 2 T3N1M0 
Stage III 
Unknown 
Cecum Female 77 Grade 2 T2N1M0 
Stage III 
Not cancer-related 





Male 65 Grade 2 T2N0M0 
Stage I 
Not applicable 




















Grade 2 T3N2Mx 
Stage III 




Grade 2 T3N2Mx 
Stage III 
 Same patient -
recurrent cancer 
Table A.5.  Correlation of KRAS G13x Targeted Region Mutations with 
Clinicopathological Data for the Patient Cohort 
KRAS G13x was the second most frequently identified KRAS mutation in our cohort.  
From a clinico-pathological perspective, this mutation was observed in a higher 
frequency in primary tumors arising in the distal colon.  The KRAS G13x mutation 
was primarilyidentified in Grade 2, Stage III adenocarcinoma. 
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A.13 Correlation of KRAS G13x and Less Common Targeted
Region Mutation with Clinicopathological Data for the 










Cause of Death 
G12x & 
G13x 
Ascending Female 86 Grade 2 T1N0M0 
Stage I 
Cancer-related 
A146x Ascending Male 53 Grade 2 T3N2M1 
Stage IV 
Cancer-related 
Transverse Male 72 Grade 2 T4N0M0 
Stage II 
Not cancer-related 




Sigmoid Male 59 Grade 3 T3N1M0 
Stage III 
Unknown 
Q61x Ascending Male 67 Grade 2 T3N0M0 
Stage II 
Not cancer-related 
A59x Sigmoid Male 48 Grade 3 T2N0M0 
Stage I 
Unknown 
Table A.5.  Correlation of KRAS G13x Targeted Region Mutations with 
Clinicopathological Data for the Patient Cohort (continued) 
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A.14 Correlation of BRAF V600E Mutation with
Clinicopathological Data for the Patient Cohort. 
Patient Demographics 






Cause of Death 
Cecum Female 81 Grade 3 T4N2M0 
Stage III 
Not cancer-related 
Cecum Female 71 Grade 3 T3N1M0 
Stage III 
Cancer-related 
Cecum Female 66 Grade 2 T3N1M0 
Stage III 
Cancer-related 
Descending Female 60 Grade 4 T4N1M0 
Stage III 
Cancer-related 
Ascending Female 90 Grade 3 T3N2M0 
Stage III 
unknown 
Ascending Male 69 Grade 2 T2N0M0 
Stage I 
Not applicable 
Transverse Female 48 Grade 2 T3N0M0 
Stage II 
Unknown 
Sigmoid Female 82 Grade 2 T1N0M0 
Stage I 
Cancer-related 





Male 64 Grade 1 T3N0M0 
Stage II 
Unknown 
Ascending Female 87 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Descending Female 69 Grade 2 T2N0M0 
Stage I 
Cancer-related 
Transverse Male 64 Grade 2 T3N0M0 
Stage II 
Cancer related 
Cecum Male 66 Adeno, NOS T3N0M0 
Stage II 
unknown 
Ascending Female 78 Grade 4 T3N0M0 
Stage II 
Cancer-related 
Transverse Female 75 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Table A.6.  Correlation of BRAF V600E Mutation with Clinicopathological Data 
for the Patient Cohort 
From a clinico-pathological perspective, the BRAF V600E  mutation was observed in 
a higher frequency in female patients (p=0.001) and in primary tumors arising in the 
proximal colon. The BRAF V600E mutation was primarily identified in Grade 2 or 3 
adenocarcinoma with localized disease. 
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A.15 Correlation of BRAF V600E Mutation with
Clinicopathological Data for Patient Cohort (continued). 
Patient Demographics 






Cause of Death 
Transverse Female 83 Grade 3 T4N0M0 
Stage II 
Not cancer-related 





Female 87 Grade 2 T3N0Mx 
Stage II 
Not cancer-related 
Right colon Female 80 synch 
#2- Grade 2 














(block #3)   
Transverse  
(block #7) 






Table A.6.  Correlation of BRAF V600E Mutation with Clinicopathological Data 
for the Patient Cohort (continued) 
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A.16 Correlation of NRAS Targeted Region Mutations with











Source Gender Age 
G13X Rectum Male 51 Grade 2 T3N1M0 
Stage III 
Unknown 






Female 70 Grade 2 T3N0M0 
Stage II 
Unknown 


















Table A.7.  Correlation of NRAS Targeted Region Mutations with 
Clinicopathological Data for the Patient Cohort 
NRAS mutations in codon 61were the most frequently NRAS mutations identified 
in our cohort.  NRAS mutations were observed in a higher frequency in male 
patients and were slightly more prevalent in primary tumors arising in the proximal 




A.17 Correlation of PIK3CA Targeted Region Mutations with









Cause of Death 
H1047X 





Male 76 Grade 2 T3N0M0 
Stage II 
Not cancer-related 
Transverse Male 72 Grade 2 T4N0M0 
Stage II 
Not cancer-related 
Transverse Female 76 Grade 4 T3N0M0 
Stage II 
Cancer-related 
Cecum Male 62 Grade 3 T3N0M0 
Stage II 
Unknown 
Colon Female 67 Grade 2 T3N0M0 
Stage II 
Cancer-related 




Ascending Male 53 Grade 2 T3N2M1 
Stage IV 
Cancer-related 
Ascending Female 48 Grade 2 T3N0M0 
Stage II 
Not applicable 
Ileocecal Male 55 Grade 2 T3N1M0 
Stage III 
Unknown 
Transverse Male 64 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Transverse Female 76 Grade 4 T3N0M0 
Stage II 
Cancer-related 
Descending Male 78 Grade 2 T4N2M0 
Stage III 
Cancer-related 




Right Colon Female 80 Grade 2 T3N0Mx 
Stage II 
Cancer-related 
G1049R Sigmoid Male 69 Grade 2 N/A Bx Cancer-related 
Table A.8.  Correlation of PIK3CA Targeted Region Mutations with 
Clinicopathological Data for the Patient Cohort 
PIK3CA mutations in exons 9 and 20 were the most frequently PIK3CA mutations 
identified in our cohort.  PIK3CA mutations were observed in equally among both 
genders and were identified in higher frequencies in primary tumors arising in the 
proximal colon. PIK3CA mutations associated with Grade 2, AJCC Stage II 
adenocarcinoma in our cohort. 
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A.18 Correlation of PIK3CA Targeted Region Mutations with











Cause of Death 
C420R Cecum Female 81 Grade 3 T4N2M0 
Stage III 
Not cancer-related 
Ascending Male 67 Grade 2 T3N0M0 
Stage II 
Not cancer-related 
Q546X Cecum Male 62 Grade 4 T1No Mx 
Stage I 
Not applicable 
Ascending Male 67 Grade 2 T2N0M0 
Stage I 
Unknown 
N345K Descending Female 60 Grade 4 T4N1M0 
Stage III 
Cancer-related 
Table A.8.  Correlation of PIK3CA Targeted Region Mutations with 
Clinicopathological Data for the Patient Cohort (continued) 
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A.19 Diversity of Concomitant Mutations and












Gender Age Source 





MMR Status:  
deficient, loss of 
MLH1/PMS2 (bx, 
resection + nodes) 
PDL-1 expression: 
30% (bx & nodes), 
75% exp in resection. 
BRAF V600E/E2/D 
Positive via IHC and 
PCR (bx, resection, 
nodes) 
PIK3CA C420R (bx, 
resection + nodes). 




Resection & nodes: 
Positive for KRAS 
A146x mutation 
Nodes: positive for 
PIK3CA E545x 
mutation.   
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological 
Features for the Patient Cohort 
Twenty-nine percent of the patients in our cohort had malignancies in which multiple 
mutations were identified.  Malignancies arising in the ascending colon demonstrated 
the greatest mutational diversity and the frequency of concomitant mutations 
gradually decreased from the transverse colon to the rectum.    
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A.20 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
Patient Demographics 










Female 60 Descending Grade 4 T4N1M0 Cancer-
related 
Bx:  BRAF V600E 
positive via IHC only; 
no mut detected via 
PCR. 
No PIK3CA mutation 
detected. 
Resection:  BRAF 




Nodes:  BRAF V600E 
via IHC only; no mut 
detected via PCR. 
Female 90 Ascending Grade 3 T4N1M0 Unknown Bx: 
MMR Status:  
Deficient / loss of 
MLH1/PMS2 
BRAF V600E 
positive via IHC only; 









Nodes:   
BRAF V600E + via 
IHC and PCR. 
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features 
for the Patient Cohort (continued) 
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A.21 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
Patient Demographics 






















Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features 
for the Patient Cohort (continued) 
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A.22 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
Patient Demographics 




















BRAF V600E positive 
via IHC and PCR. 
Resection:  
MMR Status:  
Deficient / loss 
MLH1/PMS2 
PDL-1 expression: 5% 
BRAF V600E positive 
via IHC and PCR. 






MMR status:  
Deficient / loss 
MLH1/PMS2 
Resection:  
MMR status:  






Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features 
for the Patient Cohort (continued) 
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A.23 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
 Patient Demographics 





 Cause of 
Death 
 Characterization 
of Mutations:  






T3N0M0 Unknown Resection:  
PDL-1 expression in 
TC: 3% expression 
BRAF V600E positive 
via IHC and PCR. 
Male 68 Sigmoid Grade 3 T3N0M0 Cancer-
related 
Resection:  
PDL-1 expression in 
TC:  5% expression 
KRAS mutation 
(G12x) detected 
Female 87 Ascending Grade 2 T3N0M0 Cancer-
related 
Resection:  
MMR Status:  
Deficient / loss 
MLH1/PMS2 
BRAF V600E positive 
via IHC and PCR. 





inTC: <1% expression 
KRAS mutation 
(G12x) detected 




(G12x and G13x) 
Male 67 Ascending Grade 2 T2N0M0 Unknown Resection: 
PDL-1 expression in 





Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for 
the Patient Cohort (continued) 
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A.24 Diversity of Concomitant Mutations and
Clinicopathological Features (continued).
 Patient Demographics 






 Cause of 
Death 
 Characterization of 
Mutations:  




Deficient / loss 
MLH1/PMS2 
PDL-1 expression in 
TC: <1% expression 
BRAF V600E positive 
via IHC and PCR. 
Female 76 Transverse Grade 4 T3N0M0 Cancer-
related 
Resection: 
PDL-1 expression in 




(H1047x & E545x) 
detected 
Male 64 Transverse Grade 2 T3N0M0 Cancer-
related 
Resection: 
BRAF V600E positive 
via IHC and PCR 
PIK3CA mutations 
(E545x) detected 
Male 66 Cecum Grade 2 T3N0M0 Unknown Resection: 
MMR Status:  
Deficient / loss 
MLH1/PMS2 
BRAF V600E positive 
via IHC and PCR. 
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for
the Patient Cohort (continued)
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A.25 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
 Patient Demographics 






 Cause of 
Death 
 Characterization of 
Mutations:  
Male 64 Sigmoid Grade 2 T3N0M0 Unknown Resection: 
MMR Status:  
Deficient / loss of 
MLH1/PMS2, 
MSH2/MSH6 
BRAF V600E positive 
via IHC and PCR. 
Female 51 Cecum Grade 2 T2N0M0 Not 
applicable 
Resection: 
PDL-1 expression in 
TC= 1% expression 
KRAS mutation 
(G12x) detected 







Deficient / loss 
MLH1/PMS2) 
PDL-1 expression: 
<1%; lots in IC in 
stroma 





Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for 
the Patient Cohort (continued) 
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A.26 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
 Patient Demographics 





 Cause of 
Death 
 Characterization of 
Mutations:  
Female 67 Splenic 
flexure 
Grade 2 T4N0M0 Cancer-
related 
Resection: 
MMR Status:  
Deficient / loss 
MSH2); lots in IC 
KRAS mutation 
(G13x) detected. 




Deficient / loss MSH6 
KRAS mutation 
(G12x) detected. 
Female 67 Colon, NOS Grade 2 T3N0M0 Cancer-
related 
Resection: 
MMR Status:  




Male 60 Appendix Grade 2 T1N0M0 Not cancer-
related 
Resection: 









Deficient / loss 
MLH1/PMS2 
PDL-1 expression in 
TC: <1% expression 
BRAF V600E 
positive via IHC and 
PCR. 
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for 
the Patient Cohort (continued) 
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A.27 Diversity of Concomitant Mutations and
Clinicopathological Features (continued) 
. 
 Patient Demographics 






 Cause of 
Death 
 Characterization of 
Mutations:  
Female 83 Cecum Grade 3 T3N0M0 Cancer-
related 
Resection: 
MMR Status:  
Deficient / loss 
MLH1/PMS2 
PDL-1 expression in 
TC: 1-9% expression 
BRAF V600E 
positive via IHC and 
PCR. 
Female 87 Splenic 
Flexure 
Grade 2 T3N0Mx Not cancer-
related 
Resection: 
PDL-1 expression in 
TC: <1% expression 
BRAF V600E 
positive via IHC and 
PCR. 
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for 
the Patient Cohort (continued) 
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A.28 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
 Patient Demographics 





 Cause of 
Death 
 Characterization of 
Mutations:  


















MMR status: Loss 
MLH1/PMS2 
PDL-1 expression in TC: 
10-29% expression
BRAF V600E positive via 
IHC and PCR 
PIK3CA co-mutations 
(H1047x & E545x) 
detected 
Block #6 
MMR status: Loss 
MLH1/PMS2 
PDL-1 expression in TC: 
1-9% expression
BRAF V600E positive via 
IHC and PCR 
Biopsy  
MMR status: Loss 
MLH1/PMS2) 
PDL-1 expression in TC= 
1-9% expression
BRAF V600E positive via 
IHC 
Resection: 
MMR status: Deficient / 
loss MLH1/PMS2 
PDL-1 expression in TC: 
10-29% expression
BRAF V600E positive via 
IHC and PCR. 
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for the 
Patient Cohort (continued) 
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A.29 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
 Patient Demographics 





 Cause of 
Death 
 Characterization of 
Mutations:  
Male 53 Colon, NOS Grade 2 T3N0M0 Not 
applicable 
Resection: 
MMR status:  Deficient 
/ loss PMS2 
NRAS mutation (Q61x) 
detected 












KRAS mutation (G13x) 
detected. 
Nodes: 
KRAS mutation (G13x) 
detected. 
Sacrum: 
KRAS mutation (G13x) 
detected. 
Rectum: 
KRAS mutation (G13x) 
detected 
















MMR Status: Deficient 
/ loss MLH1/PMS2 
BRAF V600E positive 
via IHC 
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for 
the Patient Cohort (continued) 
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A.30 Diversity of Concomitant Mutations and
Clinicopathological Features (continued). 
 Patient Demographics 






 Cause of 
Death 
 Characterization of 
Mutations:  


























MSI-low (loss MLH1) 
PIK3CA mutation 
(E545x) detected. 
Table A.9.  Diversity of Concomitant Mutations and Clinicopathological Features for 
the Patient Cohort (continued) 
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A.31 Mismatch Repair IHC Staining Depicting Intact MMR




Figure A.7. Mismatch Repair IHC Staining Depicting Intact MMR 
Proteins in Colon Resection.  a) Hematoxylin & Eosin stain (arrow denotes) 
malignant cells, b) MLH1 shows positive nuclear staining in tumor cells, c) 
PMS2 demonstrates positive nuclear staining in the tumor cells, d) MSH2 
demonstrates positive nuclear staining in the tumor cells, e) MSH6 
demonstrates positive nuclear staining in tumor cells. All images were taken 
at 40x magnification. 
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A.32 Mismatch Repair IHC Staining Depicting Intact MMR







Figure A.8. Mismatch Repair IHC Staining Depicting Intact MMR 
Proteins in mCRC in Lymph Node.  a) Hematoxylin & Eosin stain (arrow 
denotes) malignant cells, b) MLH1 shows positive nuclear staining in tumor 
cells, c) PMS2 demonstrates positive nuclear staining in the tumor cells, d) 
MSH2 demonstrates positive nuclear staining in the tumor cells, e) MSH6 
demonstrates positive nuclear staining in tumor cells. All images were taken 
at 40x magnification. 
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A.33 Mismatch Repair IHC Staining Depicting Deficient MMR







Figure A.9. Mismatch Repair IHC Staining Depicting Deficient MMR Proteins 
in Colon Resection.  a) Hematoxylin & Eosin stain (arrow denotes) malignant cells, 
b) MLH1 shows absence of nuclear staining in tumor cells but is present in adjacent
normal colonic epithelium which serves as an internal control c) PMS2 demonstrates
absence nuclear staining in the tumor cells, d) MSH2 demonstrates positive nuclear
staining in the tumor cells, e) MSH6 demonstrates positive nuclear staining in tumor
cells. All images were taken at 40x magnification.
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A.34 Mismatch Repair IHC Staining Depicting Deficient MMR







Figure A.10. Mismatch Repair IHC Staining Depicting Deficient MMR 
Proteins in mCRC in Lymph Node.  a) Hematoxylin & Eosin stain (arrow 
denotes) malignant cells, b) MLH1 shows absence of nuclear staining in tumor 
cells c) PMS2 demonstrates absence nuclear staining in the tumor cells, d) MSH2 
demonstrates positive nuclear staining in the tumor cells, e) MSH6 demonstrates 
positive nuclear staining in tumor cells. All images were taken at 40x 
magnification. 
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A.35 Characterization of Malignancies with Intact DNA
Mismatch Repair Proteins. 
Table A.10. Characterization of Malignancies with Intact DNA 









Source Gender Age 


















Rectum Male 35 Grade 2 T3N1M0 
Stage III 
Unknown 




Sigmoid Male 49 Grade 2 T3N1M0 
Stage III 
Unknown 











Transverse Female 66 Grade 2 T3N1M0 
Stage III 
Cancer-related 
Hepatic flexure Female 63 Grade 2 T4N1M0 
Stage III 
Not applicable 




A.36 Characterization of Malignancies with Intact DNA
Mismatch Repair Proteins (continued). 
Table A.10. Characterization of Malignancies with Intact DNA 









Source Gender Age 
Rectum Female 65 Grade 2 T3N1M0 
Stage III 
Cancer-related 
Sigmoid Female 45 Grade 2 T3N1M0 
Stage III 
Unknown 
Cecum Female 71 Grade 3 T3N1M0 
Stage III 
Cancer-related 
Ascending Male 53 Grade 2 T2N2M1 
Stage IV 
Cancer-related 





Female 70 Grade 2 T3N1M0 
Stage III 
Cancer-related 




Sigmoid Female 74 Grade 2 T4N1Mx 
Stage III 
Unknown 
Transverse Female 66 Grade 2 T3N1M1 
Stage IV 
Cancer-related 
Rectum Male 51 Grade 2 T3N1M0 
Stage III 
Unknown 
Sigmoid Male 59 Grade 3 T3N1M0 
Stage III 
Unknown 
Cecum Female 66 Grade 2 T3N1M0 
Stage III 
Cancer-related 
Descending Female 60 Grade 4 T4N1M0 
Grade III 
Cancer-related 




Rectum Male 71 Grade 2 T3N1M0 
Stage III 
Unknown 
Rectum Male 83 Grade 3 T3N2M0 
Stage III 
Unknown 
Ileocecal Male 81 Grade 2 T2N2M0 
Stage III 
Cancer-related 




A.37 Characterization of Malignancies with Intact DNA
Mismatch Repair Proteins (continued). 
Table A.10. Characterization of Malignancies with Intact DNA 

















Ascending Male 69 Grade 2 T2N0M0 
Stage I 
Not applicable 





Right colon Female 70 Grade 2 T3N0M0 
Stage II 
Unknown 




Rectum Male 68 Grade 2 T1N0M0 
Stage I 
Unknown 
Sigmoid Male 54 Grade 2 T2N0M0 
Stage I 
Not applicable 




Rectum Male 76 Grade 2 T3N0M0 
Stage II 
Not applicable 
Sigmoid Male 78 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Transverse Female 48 Grade 2 T3N0M0 
Stage II 
Unknown 
Sigmoid Male 48 Grade 3 T2N0M0 
Stage I 
Unknown 
Ascending Female 48 Grade 2 T3N0M0 
Stage II 
Not applicable 
Ascending Male 67 Grade 2 T2N0M0 
Stage I 
Unknown 
Rectum Female 83 Grade 2 T3N0M0 
Stage II 
Not applicable 









A.38 Characterization of Malignancies with Intact DNA
Mismatch Repair Proteins (continued). 
Table A.10. Characterization of Malignancies with Intact DNA 








Source Gender Age 
Splenic flexure Male 64 Grade 1 T3N0M0 
Stage II 
Unknown 
Rectum Male 55 Grade 2 T2N0M0 
Stage I 
Unknown 










Rectum Male 56 Grade 2 T3NxMx 
Stage II 
Cancer-related 




Ascending Female 86 Grade 2 T1N0M0 
Stage I 
Cancer-related 
Ascending Male 67 Grade 2 T2N0M0 
Stage I 
Unknown 




Transverse Female 69 Grade 3 T3N0M0 
Stage II 
Deceased 
Rectum Male 33 Grade 2 T2N0M0 
Stage I 
Unknown 
Transverse Female 76 Grade 4 T3N0M0 
Stage II 
Cancer-related 
Ileocecal Male 55 Grade 3 T3N0M0 
Stage II 
Unknown 
Rectum Female 65 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Sigmoid Male 83 Grade 2 T2N0M0 
Stage I 
Unknown 
Hepatic flexure Male 84 Grade 2 T2N0M0 
Stage I 
Cancer-related 
Cecum Male 76 Grade 2 T1N0M0 
Stage I 
Cancer-related 




Transverse Male 64 Grade 3 T3N0M0 
Stage II 
Cancer-related 





A.39 Characterization of Malignancies with Intact DNA
Mismatch Repair Proteins (continued). 
Table A.10. Characterization of Malignancies with Intact DNA 








Source Gender Age 
Cecum Female 55 Grade 2 T2N0M0 
Stage I 
Not applicable 




Ascending Female 66 Grade 3 T1N0M0 
Stage I 
Unknown 
Rectum Male 72 Grade 2 T1N0M0 
Stage I 
Unknown 
Cecum Male 62 Grade 3 T3N0M0 
Stage II 
Unknown 




Cecum Male 57 Grade 3 T3N0M0 
Stage II 
Unknown 
Ascending Female 78 Grade 4 T3N0M0 
Stage II 
Cancer-related 
Transverse Female 75 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Cecum Male 83 Grade 2 T1N0M0 
Stage I 
Cancer-related 
Hepatic flexure Female 66 Grade 2 T3N0M0 
Stage II 
Cancer-related 




Splenic flexure Male 89 Grade 2 T4N0M0 
Stage II 
Cancer-related 
Colon, NOS Male 51 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Rectum Male 73 Grade 2 T3N0M0 
Stage II 
Unknown 
Hepatic flexure Male 52 Grade 2 T3N0M0 
Stage II 
Unknown 
Right colon Female 73 Grade 2 T3N0M0 
Stage II 
Unknown 













A.40 Characterization of Malignancies with Intact DNA
Mismatch Repair Proteins (continued). 
Table A.10. Characterization of Malignancies with Intact DNA 






Cause of Death 
Source Gender Age 

































original bx site 








































A.41 Characterization of Malignancies with Deficient DNA
Mismatch Repair Proteins Demonstrating a Loss of 
MLH1/PMS2. 
Table A.11. Characterization of Malignancies with Deficient DNA 








Source Gender Age 




Cecum Female 72 Grade 2 T3N2N0 
Stage III 
Unknown 
Cecum Female 73 Grade 2 T4N2M0 
Stage III 
Unknown 
Ascending Female 90 Grade 3 T3N2M0 
Stage III 
Unknown 
Right colon Female 80 Grade 2 T2N0M0 
Stage I 
Unknown 








Right colon Male 83 Grade 2 T3N0Mx 
Stage II 
Cancer-related 
Transverse Male 51 Grade 2 T2N0mx 
Stage I 
Not applicable 




Hepatic flexure Male 56 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Ascending Female 87 Grade 2 T3N0M0 
Stage II 
Cancer-related 
Descending Female 69 Grade 2 T2N0M0 
Stage I 
Cancer-related 




Cecum Male 66 Grade 2 T3N0M0 
Stage II 
Unknown 
Sigmoid Male 64 Grade 2 T3N0M0 
Stage II 
Unknown 
Right Male 62 Grade 2 T3N0M0 
Stage II 
Not applicable 
Colon Female 67 Grade 2 T3N0M0 
Stage II 
Cancer-related 





A.42 Characterization of Malignancies with Deficient DNA
Mismatch Repair Proteins Demonstrating a Loss of 
MLH1/PMS2 (continued). 
Table A.11. Characterization of Malignancies with Deficient DNA 










Source Gender Age 
































































A.43 Characterization of Malignancies with Deficient DNA
Mismatch Repair Proteins Demonstrating a Loss of One 
Repair Protein. 
Table A.12. Characterization of Malignancies with Deficient DNA 








Cause of Death 
Source Gender Age 
Splenic flexure Female 67 Grade 2 T4N0M0 Cancer-related 
Cecum Male 88 Grade 2 T2N0M0 
Stage I 
Cancer-related 
Right colon Male 53 Grade 2 T3N0M0 
Stage II 
Not applicable 
Ascending Female 79 Grade 4 T3N0Mx 
Stage II 
Unknown 
A.44 Positive PD-L1 Expression in Colon Resection and






Figure A.11. Positive PD-L1 Expression in Colon Resection and Matched mCRC 
in Lymph Node:  a) Hematoxylin & Eosin stain (arrow denotes) malignant cells, b) 
Rabbit monoclonal negative reagent control c) Positive membranous staining in 70-89% 
of tumor cells, d) Hematoxylin & Eosin stained lymph node belonging to the same 
patient, e) Rabbit monoclonal negative reagent control, f) Positive membranous staining 
in 90-100% of tumor cells. All images were taken at 40x magnification. 
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A.45 Negative PD-L1 Expression in Colon Resection and






Figure A.12. Negative PD-L1 Expression in Colon Resection and Matched mCRC in 
Lymph Node:  a) Hematoxylin & Eosin stain (arrow denotes) malignant cells, b) Rabbit 
monoclonal negative reagent control with endogenous background staining noted, c) 
Negative membranous staining in tumor cells but positive staining in macrophages in 
microenvironment (internal positive control)  d) Hematoxylin & Eosin stained lymph 
node with mCRC belonging to the same patient, e) Rabbit monoclonal negative reagent 
control, f) Negative membranous staining of tumor cells. Staining of tumor-infiltrating 
immune cells is noted.  All images were taken at 40x magnification. 
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A.46 Characterization of PD-L1 and Clinicopathological





Table A.13.  Characterization of PD-L1 and Clinicopathological Features in 
Patient Cohort. 
PD-L1 Expression levels varied among matched samples in the cohort.  PD-L1 
expression was observed more frequently in tumors arising in the sigmoid and 
proximal colon.  Tumors demonstrating the greatest percentage of PD-L1 arose in the 
cecum.     
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A.47 Characterization of PD-L1 and Clinicopathological
Features in Patient Cohort (continued). 
 Table A.13.  Characterization of PD-L1 and Clinicopathological Features in 
Patient Cohort (continued)  
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A.48 Diversity of Mutations and Clinicopathological Features













































mutation – No 
mutation 
identified via 





detected in any 





detected in any 








Table A.14.  Diversity of Mutations and Clinicopathological Features in Patients with 
Synchronous Malignancies. 
Twenty-nine percent of the patients in our cohort had malignancies in which multiple 
mutations were identified.  Malignancies arising in the ascending colon demonstrated the 
greatest mutational diversity and the frequency of concomitant mutations gradually 
decreased from the transverse colon to the rectum.    
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A.49 Diversity of Mutations and Clinicopathological Features
in Patients with Synchronous Malignancies (continued). 
 Patient Demographics 
































mutation – No 
mutation 
identified via 





detected in any 





detected in any 









Table A.14.  Diversity of Mutations and Clinicopathological Features in Patients with 
Synchronous Malignancies (continued) 
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A.50 Diversity of Mutations and Clinicopathological Features
in Patients with Synchronous Malignancies (continued). 
 
Patient Demographics 




























NA MMR Status:  
deficient; loss 
of MLH1/PMS2 
in both samples. 
PDL-1 
Expression: 


























Table A.14.  Diversity of Mutations and Clinicopathological Features in Patients with 
Synchronous Malignancies (continued) 
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A.51 Diversity of Mutations and Clinicopathological Features
in Patients with Synchronous Malignancies (continued). 
Patient Demographics 








of Mutations:  
Treatment 
Summary: 
Male 78 Descending Blocks 








in both lesions. 
PDL-1 
Expression: 
Block #3: <1% 
expression in TC; 
Block #8:  no 
expression in TC. 
BRAF mutation – 
No BRAF V600E 
mutation 
identified via IHC 




Block #3-  KRAS 
mutation G12x 
identified. 



















Table A.14.  Diversity of Mutations and Clinicopathological Features in Patients with 
Synchronous Malignancies (continued) 
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A.52 Diversity of Mutations and Clinicopathological Features
in Patients with Synchronous Malignancies. 
 
Patient Demographics 



























MMR Status:  
Proficient/ 















detected in B3; 
G12X mutation 












Table A.14.  Diversity of Mutations and Clinicopathological Features in Patients with 
Synchronous Malignancies (continued) 
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A.53 Diversity of Mutations and Clinicopathological Features






























Blocks #B6 and 
#B10: 
MSI- Status:   
B6- Deficient / 
loss MLH1/PMS2 
B10- Deficient / 
loss MLH1 
PDL-1 Expression: 
no expression in 
TC.  
BRAF V600E 
mutation –  
B6- No mutation 
identified via IHC 
or PCR 
B10- yielded 
invalid results via 
PCR; IHC stain 















Table A.14.  Diversity of Mutations and Clinicopathological Features in Patients with 
Synchronous Malignancies (continued) 
 
107 
A.54 Diversity of Mutations and Clinicopathological Features











of Mutations:  Treatment 
Summary: 
Gender Age Source 














markers (IHC):  



































Table A.15.  Diversity of Mutations and Clinicopathological Features in Patients with 
Recurrent Malignancies. 
Recurrent malignancies demonstrated mutations that were similar to the original 
malignancy.  
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A.55 Diversity of Mutations and Clinicopathological Features











of Mutations:  
Treatment 
Summary: 
Female  90 Recurrence: 


























Table A.15.  Diversity of Mutations and Clinicopathological Features in Patients with 
Recurrent Malignancies (continued) 
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A.56 Diversity of Mutations and Clinicopathological Features































MMR status:  
deficient; both 
samples 
demonstrated a loss 
of MLH1/PMS2. 
PDL-1 Expression: 
Block 2:  10-29% 
expression in TC. 
Block 6: 1-9% 




positive via IHC 
and PCR  
KRAS mutation 
(PCR)- no mutation 




Block 2:  H1047X 
and E545X 
mutations detected. 
Block 6:  No 
mutation detected. 
Not avail 
Table A.15.  Diversity of Mutations and Clinicopathological Features in Patients with 
Recurrent Malignancies (continued) 
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A.57 Diversity of Mutations and Clinicopathological Features












of Mutations:  
 Treatment 
Summary: 


















































Table A.15.  Diversity of Mutations and Clinicopathological Features in Patients with 
Recurrent Malignancies (continued) 
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A.58 Diversity of Mutations and Clinicopathological Features










of Mutations:  
Treatment 
Summary: 









Unknown MMR - Status: 
proficient;  intact 
in resection  
PDL-1 
Expression: <1% 




















site recurrence.  
Patient chose 
observation.     
Table A.15.  Diversity of Mutations and Clinicopathological Features in Patients with 
Recurrent Malignancies (continued) 
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A.59 Diversity of Mutations and Clinicopathological Features
in Patients with Recurrent Malignancies (continued). 
Patient Demographics 










of Mutations:  
Treatment 
Summary: 









Colon:  1-9% 
expression in TC. 
Nodes: no 








in both samples. 
PIK3CA 
mutation (PCR)-  
No mutation 












Table A.15.  Diversity of Mutations and Clinicopathological Features in Patients with 
Recurrent Malignancies (continued) 
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A.60 Diversity of Mutations and Clinicopathological Features
in Patients with Recurrent Malignancies (continued). 
Patient Demographics 

























No expression in 

















:  Rectum 
Grade 2 Refers to 
original 
staging 








Table A.15.  Diversity of Mutations and Clinicopathological Features in Patients with 
Recurrent Malignancies (continued) 
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of Mutations:  
Treatment 
Summary: 




Unknown MMR IHC:  















































Table A.16.  Characterization of Chemoresistant Malignancies.   
Chemoresistance was presumed based on multiple courses of cytotoxic therapies and 
treatment notes.  Malignancies arising in the rectum were the most frequent source of 
chemoresistant tumors in our cohort, however, this finding is not generalizable due to the 
small number of samples in this category.   
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of Mutations:  
Treatment 
Summary: 
Female 65 Rectum Grade 
2 





(IHC):   























in bx; resection 






















Table A.16.  Characterization of Chemoresistant Malignancies (Continued). 
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Summary  of 
Mutations:  Treatment 
Summary: 




Unknown MMR proteins: 











































Table A.16.  Characterization of Chemoresistant Malignancies (continued). 
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A.64 Characterization of Chemoresistant Malignancies
(continued). 
 Patient Demographics 




















Intact in resection 
and nodes. 
PDL-1 Expression- 
no expression in 




































Table A.16.  Characterization of Chemoresistant Malignancies (continued). 
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A.65 Characterization of Chemoresistant Malignancies
(continued). 
Patient Demographics 







of Mutations:  
Treatment 
Summary: 








Deceased MMR proteins 
(IHC):  Intact in 










































Table A.16.  Characterization of Chemoresistant Malignancies (continued). 
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A.66 Characterization of Chemoresistant Malignancies
(continued). 
Patient Demographics 








of Mutations:  
Treatment 
Summary: 








































Table A.16.  Characterization of Chemoresistant Malignancies (continued). 
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 Cause of 
Death Characterization 
of Mutations:  
Treatment 
Summary: 
Male 53 Right 
colon 
Grade 2 T3 N0 M0 
Stage II  
Not 
applicable 
MMR status:  






























Folfox + Avastin 
Folfiri 
Table A.16.  Characterization of Chemoresistant Malignancies (continued). 
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 Cause of 
Death Characterization 
of Mutations:  
Treatment 
Summary: 









































Table A.16.  Characterization of Chemoresistant Malignancies (continued). 
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A.69 Clinicopathological Features of Malignancies in Which









 Source Gender Age 
Rectum Male 46 Grade 3 T2N0M0 Unknown 
Hepatic 
Flexure 
Female 65  Grade 2 T3N0M0  Cancer 
related 
Rectum Male 78 
Rectum Female 65 Grade 2 T3N1M0 Cancer-
related 




Female 70 Grade 2 T3N1M0 Cancer-
related 
Rectum Male 83 Grade 3 T3N2M0 Unknown 
Rectum Male 68 Grade 2 T1N0M0 Unknown 
Rectum Male 76 Grade 2 T3N0M0 Not 
applicable 
Sigmoid Male 78 Grade 2 T3N0M0 Cancer-
related 
Transverse Male 82 Grade 2 T4N0M0 Cancer-
related 
Male Rectum 55 Grade 2 T2N0M0 Unknown 
Male Rectum 56 Grade2 T3NxMx Cancer-
related 
Table A.17.  Clinicopathological Features of Malignancies 
in Which No Mutations Were Detected.  No mutations were 
detected in a subset of samples in this study.  Of these, a 
majority of the primary tumors arose in the rectum and 
belonged to males.   
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A.70 Clinicopathological Features of Malignancies in Which









 Source Gender Age 
Male Sigmoid 56 Grade 2 T2N0M0 Not 
cancer-
related 
Rectum Male 33 Grade 2 T2N0M0 Unknown 
Rectum Female 65 Grade 2 T3N0M0 Cancer-
related 
Transverse Male 72 Grade 2 T3N0M0 Not 
cancer-
related 
Ascending Female 66 Grade 2 T1N0M0 Unknown 
Sigmoid Male 80 Grade 2 T3N0M0 




Female 66 Grade 2 T3N0M0 
Right colon Male 68 Grade 2 T1N0M0 Not 
cancer-
related 
Rectum Male 73 Grade 2 T3N0M0 Unknown 
Hepatic 
flexure 
Male 52 Grade 2 T3N0M0 Unknown 
Sigmoid Male 58 Grade 1 T1N0M0 Not 
cancer-
related 










Cecum Male 83 Grade 2 T2N0M0 Unknown 
Table A.17.  Clinicopathological Features of Malignancies 
in Which No Mutations Were Detected (continued). 
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A.71 Clinicopathological Features of Patients Who Died From
Cancer-Related Causes. 
Table A.18.  Clinicopathological Features of Patients Who Died From 
Cancer-Related Causes.  Thirty-seven percent of the patients in this cohort 
expired due to cancer-related causes.  Interestingly, 57% of the patients that 
passed away were originally diagnosed with localized disease (white rows) or 
synchronous malignancies (green rows) vs. those originally diagnosed with 
metastatic disease (yellow rows). Over 40% of the patients who passed away 
from CRC had primary tumors arising in the proximal colon.  
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